≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Secondary polycythaemia

DOID EFO Endpoint Browser PheWeb

D3_SCNDPOLYCYTHAEMIA

polycythemia: Abnormally high mass or concentration of red blood cells in the blood, either due to an increase in erythropoiesis or a decrease in plasma volume.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D75.1
  • Hospital discharge: ICD-9 — 2890
  • Hospital discharge: ICD-8 — 28900
  • Cause of death: ICD-10 — D75.1
  • Cause of death: ICD-9 — 2890
  • Cause of death: ICD-8 — 28900

2 out of 7 registries used, show all original rules.

950

4. Check minimum number of events

None

950

5. Include endpoints

None

950

6. Filter based on genotype QC (FinnGen only)

921

Control definitions (FinnGen only)

Control exclude
D3_BLOODOTHER

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D75
Name in latin
Polycythaemia secundaria

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 5793 1925 3795
Only index persons 4662 1564 3098
Unadjusted period prevalence (%)
Whole population 0.09 0.06 0.11
Only index persons 0.10 0.06 0.12
Median age at first event (years)
Whole population 58.75 60.79 57.65
Only index persons 57.47 60.07 56.16

-FinnGen-

Key figures

All Female Male
Number of individuals 921 326 595
Unadjusted period prevalence (%) 0.22 0.12 0.27
Median age at first event (years) 58.55 57.35 59.20

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
950
Matched controls
9500
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D75.1
ICD-10 Finland
Secondary polycythaemia
16384.0
307.7
886
5
D45
ICD-10 Finland
Polycythaemia vera
75.8
242.4
131
20
XW000
NOMESCO Finland
Bone marrow biopsy
11.3
121.9
136
138
SPAT1074
SPAT
Venesection
38.1
86.9
54
15
TPH00
NOMESCO Finland
Phlebotomy
80.1
53.7
60
8
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
4.6
53.5
143
356
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
524.8
50.9
50
*
D75.0
ICD-10 Finland
Familial erythrocytosis
513.7
49.9
49
*
28900
ICD-8 Finland
Other disease of blood and blood-forming organs, Polycythaemia, secondary
+∞
48.3
46
*
G47.3
ICD-10 Finland
Sleep apnoea
2.8
47.7
363
1732
T90
ICPC
Diabetes non-insulin dependent
2.8
46.2
348
1647
103
Kela drug reimbursment
Diabetes, insulin-treated
2.7
45.4
372
1834
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.7
44.8
340
1610
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.7
44.8
347
1661
A10BA02
ATC
metformin; oral
2.6
43.1
383
1955
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
17.3
42.0
35
21
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
9.3
39.2
48
54
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
35.1
191
749
L01XX05
ATC
hydroxycarbamide; oral
12.6
34.3
34
28
SPAT1262
SPAT
Handing over of treatment supplies
2.7
33.1
227
1002
E29.1
ICD-10 Finland
Testicular hypofunction
7.2
32.9
50
73
R71
ICD-10 Finland
Abnormality of red blood cells
50.7
32.7
39
8
C03CA01
ATC
furosemide; systemic
2.3
30.9
343
1878
J96.1
ICD-10 Finland
Chronic respiratory failure
5.7
27.2
52
96
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.7
26.4
158
646
C01AA05
ATC
digoxin; systemic
3.3
25.9
107
355
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
25.7
520
3520
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.4
25.6
212
1011
A10BH01
ATC
sitagliptin; oral
2.8
24.5
137
539
I50.9
ICD-10 Finland
Heart failure, unspecified
2.5
24.1
177
797
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.2
24.1
100
332
R5140
NOMESCO Finland
Monitoring the use of the aid
2.5
23.5
167
740
A10BJ06
ATC
semaglutide; parenteral
3.3
23.2
92
297
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.1
22.4
284
1604
C07AB07
ATC
bisoprolol; oral
1.9
22.1
508
3525
I10
ICD-10 Finland
Essential (primary) hypertension
2.0
21.8
635
4768
D75.2
ICD-10 Finland
Essential thrombocytosis
117.7
21.7
23
*
205
Kela drug reimbursment
Chronic hypertension
2.0
21.2
289
1671
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.7
20.7
118
468
E66.8
ICD-10 Finland
Other obesity
3.5
20.6
73
219
B99
ICPC
Blood/lymph/spleen disease other
42.7
20.5
25
6
C03DA01
ATC
spironolactone; oral
2.4
20.4
154
699
207
Kela drug reimbursment
Chronic arrhythmias
2.3
20.3
185
912
C07AB02
ATC
metoprolol; systemic
2.2
20.0
214
1126
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.1
19.9
88
303
A10AE04
ATC
insulin glargine; parenteral
2.5
19.4
131
564
M04AA01
ATC
allopurinol; systemic
2.3
19.2
159
751
R03BB04
ATC
tiotropium bromide; inhalant
2.5
19.0
130
563
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
56.2
19.0
22
*
A10BK03
ATC
empagliflozin; oral
2.4
18.4
141
644
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.0
18.1
233
1309
SPAT1249
SPAT
Treatment-related counselling outside office
1.9
18.1
366
2393
C08CA01
ATC
amlodipine; oral
1.8
17.9
402
2713
J44
ICD-10 Finland
Other chronic obstructive pulmonary disease
5.1
17.5
37
75
E66.00
ICD-10 Finland
Metabolic syndrome
3.0
17.3
81
288
R06.0
ICD-10 Finland
Dyspnoea
1.9
17.2
288
1765
R79.8
ICD-10 Finland
Other specified abnormal findings of blood chemistry
15.1
17.2
28
19
A10BK01
ATC
dapagliflozin; oral
2.6
16.8
107
447
E66.01
ICD-10 Finland
Obesity due to excess calories
2.5
16.4
108
458
TPH00, ,
SPAT
40.8
16.4
20
5
XG466
NOMESCO Finland
Sleep oxymetry
3.6
16.0
53
152
N06AX12
ATC
bupropion; oral
2.8
16.0
86
330
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
15.7
155
784
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
3.5
15.7
54
159
D58.2
ICD-10 Finland
Other haemoglobinopathies
+∞
15.7
15
*
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
6.6
15.4
25
39
121
Kela drug reimbursment
Severe hypofunction of sexual glands
5.3
15.4
31
60
B01AA03
ATC
warfarin; systemic
2.0
15.3
197
1100
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
3.0
14.9
67
233
R03AC02
ATC
salbutamol; inhalant
1.7
14.4
512
3862
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.3
14.4
124
593
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
2.8
14.3
72
267
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.8
14.2
253
1567
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.0
14.0
175
964
201
Kela drug reimbursment
Chronic cardiac insufficiency
2.8
13.6
70
262
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
3.3
13.3
50
156
N02AX02
ATC
tramadol; systemic, rectal
1.7
12.9
428
3139
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
2.8
12.9
65
241
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
1.9
12.8
194
1139
I50.0
ICD-10 Finland
Congestive heart failure
2.5
12.8
85
362
OAB50, ,
SPAT
2.3
12.7
98
447
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
6.1
12.6
22
37
C09AA02
ATC
enalapril; systemic
1.9
12.6
196
1159
2890X
ICD-9 Finland
Other diseases of blood and blood-forming organs, Polycythaemia, secondary[ERYTHROCYTOSIS SECUNDARIA, NUD]
+∞
12.5
12
*
E66.9
ICD-10 Finland
Obesity, unspecified
3.4
12.5
44
132
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.4
12.4
86
373
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
3.3
12.3
46
143
WX723
NOMESCO Finland
CPAP therapy
2.8
12.3
65
247
I48.1
ICD-10 Finland
Persistent atrial fibrillation
3.0
12.2
56
197
A10BJ02
ATC
liraglutide; parenteral
3.4
12.2
43
129
C02AC05
ATC
moxonidine; oral
2.8
11.9
62
234
H02AB06
ATC
prednisolone; systemic
1.6
11.8
446
3354
WX780
NOMESCO Finland
Remote monitoring CPAP
2.7
11.6
65
255
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.8
11.6
189
1133
N06AX11
ATC
mirtazapine; oral
1.7
11.5
316
2191
Y28
ICPC
Limited function/disability (Y)
13.8
11.5
19
14
SPAT1377
SPAT
Polysomnography
3.3
11.3
43
135
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.0
11.3
127
671
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
2.7
11.2
60
230
A10AB05
ATC
insulin aspart; parenteral
2.3
11.1
88
405
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
43.8
10.9
13
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.8
10.9
177
1059
J45.9
ICD-10 Finland
Asthma, unspecified
1.8
10.7
177
1062
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
10.4
212
1354
ZXE00
NOMESCO Finland
One hour or less
1.6
10.1
341
2471
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
3.2
10.1
39
124
A02BC02
ATC
pantoprazole; systemic
1.6
10.1
633
5285
SPAT1260
SPAT
Consultation of another employee
1.8
10.0
158
935
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
1.9
9.8
132
742
M10.9
ICD-10 Finland
Gout, unspecified
2.2
9.8
82
387
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.6
9.8
312
2229
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.9
9.8
122
669
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
9.2
9.5
19
21
E83.1
ICD-10 Finland
Disorders of iron metabolism
10.2
9.5
18
18
SPAT1263
SPAT
Sampling
1.6
9.5
360
2671
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.8
9.5
146
856
TFP20
NOMESCO Finland
Cardiodefibrillation
2.2
9.5
83
399
R07.4
ICD-10 Finland
Chest pain, unspecified
1.6
9.4
271
1885
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
2.7
9.4
50
191
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
3.8
9.4
28
75
J45.8
ICD-10 Finland
Mixed asthma
3.4
9.4
33
99
C09AA05
ATC
ramipril; oral
1.6
9.3
249
1703
L28
ICPC
Limited function/disability (L)
1.8
9.2
167
1029
I48.2
ICD-10 Finland
Chronic atrial fibrillation
2.5
9.1
55
224
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.6
9.1
255
1761
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
37.1
9.0
11
*
N06AB10
ATC
escitalopram; oral
1.7
8.9
175
1103
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.7
8.8
165
1024
C09CA01
ATC
losartan; oral
1.6
8.8
248
1714
R03AK06
ATC
salmeterol and fluticasone; inhalant
1.8
8.8
136
799
R53
ICD-10 Finland
Malaise and fatigue
1.6
8.8
227
1536
N07BA03
ATC
varenicline; oral
2.5
8.7
56
235
Z72.0
ICD-10 Finland
Tobacco use
3.1
8.7
36
120
I42.0
ICD-10 Finland
Dilated cardiomyopathy
3.1
8.7
36
120
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.1
8.7
87
441
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
2.1
8.6
79
386
C10AA01
ATC
simvastatin; oral
1.5
8.6
382
2918
I50.1
ICD-10 Finland
Left ventricular failure
2.5
8.5
54
225
D70.82
ICD-10 Finland
Drug-induced neutropenia
90.8
8.4
9
*
I27.9
ICD-10 Finland
Pulmonary heart disease, unspecified
12.9
8.4
14
11
Q21.81
ICD-10 Finland
Eisenmenger's syndrome
+∞
8.3
8
*
SPAT1225
SPAT
Implementation of podiatry rehabilitation plan
3.2
8.3
32
102
SPAT1281
SPAT
Other administrative function
2.1
8.1
74
362
JN3AD
NOMESCO Finland
Abdominal CT examination
1.8
8.0
128
758
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
3.5
8.0
27
79
C08CA02
ATC
felodipine; oral
2.0
7.9
89
470
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.9
7.9
110
624
A10BB12
ATC
glimepiride; oral
2.2
7.9
69
332
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.5
7.7
352
2688
M54.5
ICD-10 Finland
Low back pain
1.5
7.7
324
2434
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
1.6
7.7
219
1510
N06AB06
ATC
sertraline; oral
1.9
7.7
100
555
I50
ICD-10 Finland
Heart failure
3.0
7.6
33
113
R03AL03
ATC
vilanterol and umeclidinium bromide; inhalant
3.9
7.6
22
58
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
2.8
7.5
37
136
R03BA05
ATC
fluticasone; inhalant
1.7
7.4
155
990
212
Kela drug reimbursment
Gout
3.8
7.4
22
59
M10
ICD-10 Finland
Gout
2.4
7.4
51
222
SPAT1309
SPAT
Guidance related to psychoactive substances / risk behaviour
3.0
7.3
32
110
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
9.5
7.3
14
15
XFE00
NOMESCO Finland
Epicardial ultrasonography
3.3
7.3
27
84
A10BH02
ATC
vildagliptin; oral
3.4
7.3
25
74
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
1.9
7.3
95
528
J01AA02
ATC
doxycycline; systemic
1.5
7.2
702
6184
A10BJ01
ATC
exenatide; parenteral
4.5
7.2
17
38
TPH07
NOMESCO Finland
Cathetrisation of artery
1.8
7.2
109
635
H02AB09
ATC
hydrocortisone; systemic
3.3
7.1
26
80
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
3.3
7.1
26
80
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.7
7.1
123
745
T82
ICPC
Obesity
2.5
7.1
42
170
WZC00, ,
SPAT
1.7
7.1
131
809
R03AK07
ATC
formoterol and budesonide; inhalant
1.6
7.1
185
1249
B04
ICPC
Blood symptom/complaint
10.1
7.0
13
13
SPAT1254
SPAT
Administration of medicine
1.7
7.0
124
755
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.7
7.0
125
763
A12BA01
ATC
potassium chloride; oral
2.6
7.0
39
153
K99
ICPC
Cardiovascular disease other
3.1
7.0
29
97
GX2D5
NOMESCO Finland
Sleep oximetry
7.6
6.9
15
20
J01MA02
ATC
ciprofloxacin; systemic
1.5
6.9
342
2644
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.6
6.8
172
1150
C03AA03
ATC
hydrochlorothiazide; oral
2.0
6.8
77
408
R95
ICPC
Chron obstructive pulmonary disease
2.7
6.8
35
132
J01DB01
ATC
cefalexin; oral
1.5
6.8
746
6687
OAB75, ,
SPAT
3.1
6.8
27
88
D75.8
ICD-10 Finland
Other specified diseases of blood and blood-forming organs
40.3
6.8
8
*
WX110
NOMESCO Finland
Infiltration anesthesia
1.5
6.8
634
5503
F17.29
ICD-10 Finland
Addiction caused by tobacco UNS
3.3
6.7
24
73
H03AA01
ATC
levothyroxine sodium; systemic
1.6
6.6
169
1133
N05BA04
ATC
oxazepam; oral
1.5
6.6
222
1584
G04CA02
ATC
tamsulosin; oral
1.5
6.6
249
1820
SPAT1310
SPAT
Counselling related to known health issue
1.5
6.6
259
1909
N05CF02
ATC
zolpidem; oral
1.6
6.6
149
970
C09DA01
ATC
losartan and diuretics; oral
1.8
6.5
101
594
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
2.3
6.4
45
197
ZXD05
NOMESCO Finland
Urgent procedure
1.5
6.4
255
1881
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.6
6.4
160
1066
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
1.8
6.4
97
565
Z02.7
ICD-10 Finland
Issue of medical certificate
2.0
6.3
70
368
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
2.1
6.3
61
305
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.5
6.3
234
1703
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
1.8
6.3
88
501
A10AE05
ATC
insulin detemir; parenteral
2.2
6.3
53
252
D70.89
ICD-10 Finland
Neutropenic splenomegaly
26.9
6.2
8
*
S01
ICPC
Pain/tenderness of skin
2.3
6.2
44
194
K80.0
ICD-10 Finland
Calculus of gallbladder with acute cholecystitis
2.5
6.2
38
157
N06CA01
ATC
amitriptyline and psycholeptics; systemic
1.9
6.2
83
466
R52.9
ICD-10 Finland
Pain, unspecified
1.8
6.2
92
534
160
Kela drug reimbursment
exenatide
3.0
6.1
26
88
JAF30
NOMESCO Finland
Repair of umbilical hernia using prosthetic material
2.9
6.1
28
99
B01AB05
ATC
enoxaparin; parenteral
1.5
6.1
264
1979
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.4
6.1
454
3753
N05AH04
ATC
quetiapine; oral
1.6
6.1
158
1064

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Hematology
82 [38004501]
1.2e+00
2.9e+00
3.8e+00
1.0e+50
4.7e+00
3.9e+00
2.4e+00
cases:2.52%
controls:0.75%
cases:7.24%
controls:0.41%
cases:5.92%
controls:0.14%
cases:44.19%
controls:0.00%
cases:12.31%
controls:0.12%
cases:19.70%
controls:0.49%
cases:10.78%
controls:1.07%
23
68
889
9027
66
37
846
9058
54
13
858
9082
403
0
509
9095
112
11
798
9056
172
43
701
8722
80
79
662
7305
androstanolone
G03BB02 [21602513]
2.7e+00
2.9e+00
2.9e+00
—
2.6e+00
2.6e+00
2.5e+00
cases:9.43%
controls:0.69%
cases:8.77%
controls:0.55%
cases:2.85%
controls:0.15%
—
—
cases:2.20%
controls:0.17%
cases:7.33%
controls:0.58%
cases:8.22%
controls:0.70%
86
63
826
9032
80
50
832
9045
26
14
886
9081
—
20
15
890
9052
64
51
809
8714
61
52
681
7332
androstanolone
A14AA01 [21600917]
2.7e+00
2.9e+00
3.0e+00
—
2.6e+00
2.6e+00
2.5e+00
cases:9.54%
controls:0.70%
cases:9.10%
controls:0.56%
cases:2.96%
controls:0.15%
—
—
cases:2.20%
controls:0.17%
cases:7.56%
controls:0.60%
cases:8.76%
controls:0.80%
87
64
825
9031
83
51
829
9044
27
14
885
9081
—
20
15
890
9052
66
53
807
8712
65
59
677
7325
Polycythaemia vera
D45 [45595761]
2.7e+00
4.7e+00
1.0e+50
—
—
4.3e+00
4.1e+00
cases:0.99%
controls:0.07%
cases:5.59%
controls:0.05%
cases:3.29%
controls:0.00%
—
—
—
—
cases:5.04%
controls:0.07%
cases:6.33%
controls:0.11%
9
6
903
9089
51
5
861
9090
30
0
882
9095
—
—
44
6
829
8759
47
8
695
7376
Internal Medicine
11 [38004456]
6.8e-01
1.1e+00
2.1e+00
6.8e+00
2.3e+00
1.8e+00
9.3e-01
cases:34.54%
controls:21.08%
cases:22.15%
controls:8.50%
cases:9.87%
controls:1.28%
cases:45.18%
controls:0.09%
cases:13.08%
controls:1.54%
cases:33.68%
controls:7.84%
cases:38.41%
controls:19.68%
315
1917
597
7178
202
773
710
8322
90
116
822
8979
412
8
500
9087
119
140
791
8927
294
687
579
8078
285
1453
457
5931
Erythropoietin (EPO) [Units/volume] in Serum or Plasma
15061-5 [3024172]
3.2e+00
5.7e+00
1.0e+50
1.0e+50
—
4.1e+00
2.5e+00
cases:4.61%
controls:0.19%
cases:20.83%
controls:0.09%
cases:22.92%
controls:0.00%
cases:1.64%
controls:0.00%
—
—
cases:4.58%
controls:0.08%
cases:5.26%
controls:0.46%
42
17
870
9078
190
8
722
9087
209
0
703
9095
15
0
897
9095
—
40
7
833
8758
39
34
703
7350
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
2.5e+00
2.7e+00
2.9e+00
—
2.7e+00
2.4e+00
2.2e+00
cases:11.84%
controls:1.12%
cases:10.96%
controls:0.86%
cases:3.51%
controls:0.21%
—
—
cases:2.86%
controls:0.20%
cases:8.93%
controls:0.84%
cases:10.11%
controls:1.25%
108
102
804
8993
100
78
812
9017
32
19
880
9076
—
26
18
884
9049
78
74
795
8691
75
92
667
7292
JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method
80187-8 [21494670]
3.9e+00
5.9e+00
1.0e+50
1.0e+50
—
—
2.4e+00
cases:4.06%
controls:0.09%
cases:16.34%
controls:0.05%
cases:16.67%
controls:0.00%
cases:1.21%
controls:0.00%
—
—
—
—
cases:3.23%
controls:0.30%
37
8
875
9087
149
5
763
9090
152
0
760
9095
11
0
901
9095
—
—
24
22
718
7362
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
2.8e-01
2.0e+00
5.0e+00
—
2.7e+00
1.4e+00
1.0e+00
cases:2.41%
controls:1.83%
cases:6.25%
controls:0.91%
cases:10.53%
controls:0.08%
—
—
cases:1.87%
controls:0.13%
cases:3.89%
controls:0.96%
cases:7.68%
controls:2.87%
22
166
890
8929
57
83
855
9012
96
7
816
9088
—
17
12
893
9055
34
84
839
8681
57
212
685
7172
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.3e-01
1.7e+00
4.8e+00
1.0e+50
2.8e+00
1.9e+00
7.3e-01
cases:1.97%
controls:1.74%
cases:3.95%
controls:0.77%
cases:9.43%
controls:0.09%
cases:1.64%
controls:0.00%
cases:1.21%
controls:0.08%
cases:4.81%
controls:0.73%
cases:6.20%
controls:3.07%
18
158
894
8937
36
70
876
9025
86
8
826
9087
15
0
897
9095
11
7
899
9060
42
64
831
8701
46
227
696
7157
Normoblasts [#/volume] in Blood
715-3 [3021589]
4.9e-01
1.2e+00
2.7e+00
4.1e+00
1.3e+00
1.1e+00
8.3e-01
cases:15.57%
controls:10.17%
cases:22.26%
controls:7.91%
cases:20.18%
controls:1.61%
cases:3.07%
controls:0.05%
cases:5.60%
controls:1.53%
cases:20.96%
controls:8.31%
cases:29.51%
controls:15.47%
142
925
770
8170
203
719
709
8376
184
146
728
8949
28
5
884
9090
51
139
859
8928
183
728
690
8037
219
1142
523
6242
Sleep apnoea
G47.3 [45562094]
7.2e-01
1.0e+00
1.1e+00
4.2e+00
1.1e+00
1.7e+00
1.4e+00
cases:11.40%
controls:5.89%
cases:10.09%
controls:3.82%
cases:2.52%
controls:0.82%
cases:3.51%
controls:0.05%
cases:3.19%
controls:1.05%
cases:17.18%
controls:3.82%
cases:24.93%
controls:7.73%
104
536
808
8559
92
347
820
8748
23
75
889
9020
32
5
880
9090
29
95
881
8972
150
335
723
8430
185
571
557
6813
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
2.9e-01
1.2e+00
2.7e+00
4.0e+00
1.1e+00
9.5e-01
7.5e-01
cases:18.31%
controls:14.34%
cases:26.10%
controls:9.27%
cases:26.21%
controls:2.24%
cases:2.96%
controls:0.05%
cases:5.71%
controls:2.02%
cases:19.93%
controls:8.81%
cases:31.81%
controls:18.09%
167
1304
745
7791
238
843
674
8252
239
204
673
8891
27
5
885
9090
52
183
858
8884
174
772
699
7993
236
1336
506
6048
Hypogonadotropic hypogonadism
E23.04 [2000501472]
2.9e+00
3.2e+00
—
1.0e+50
—
2.5e+00
2.2e+00
cases:1.75%
controls:0.10%
cases:2.08%
controls:0.09%
—
—
cases:0.55%
controls:0.00%
—
—
cases:1.72%
controls:0.15%
cases:2.43%
controls:0.27%
16
9
896
9086
19
8
893
9087
—
5
0
907
9095
—
15
13
858
8752
18
20
724
7364
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.0e+00
1.4e+00
3.3e+00
—
2.1e+00
1.6e+00
1.3e+00
cases:4.71%
controls:1.79%
cases:3.40%
controls:0.85%
cases:1.75%
controls:0.07%
—
—
cases:0.77%
controls:0.10%
cases:3.21%
controls:0.68%
cases:6.20%
controls:1.76%
43
163
869
8932
31
77
881
9018
16
6
896
9089
—
7
9
903
9058
28
60
845
8705
46
130
696
7254
dapagliflozin; oral
A10BK01 [1123890]
1.7e+00
2.0e+00
2.1e+00
—
1.9e+00
1.7e+00
1.1e+00
cases:4.61%
controls:0.90%
cases:5.92%
controls:0.88%
cases:1.97%
controls:0.24%
—
—
cases:2.20%
controls:0.33%
cases:4.81%
controls:0.91%
cases:6.33%
controls:2.11%
42
82
870
9013
54
80
858
9015
18
22
894
9073
—
20
30
890
9037
42
80
831
8685
47
156
695
7228
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
4.2e-01
1.9e+00
4.1e+00
—
2.1e+00
1.5e+00
8.0e-01
cases:3.62%
controls:2.40%
cases:8.55%
controls:1.32%
cases:8.44%
controls:0.15%
—
—
cases:1.65%
controls:0.21%
cases:6.41%
controls:1.45%
cases:8.63%
controls:4.06%
33
218
879
8877
78
120
834
8975
77
14
835
9081
—
15
19
895
9048
56
127
817
8638
64
300
678
7084
Testicular hypofunction
E29.1 [45576454]
3.0e+00
2.4e+00
—
1.0e+50
—
2.9e+00
2.1e+00
cases:2.08%
controls:0.11%
cases:0.99%
controls:0.09%
—
—
cases:0.55%
controls:0.00%
—
—
cases:1.37%
controls:0.08%
cases:2.43%
controls:0.31%
19
10
893
9085
9
8
903
9087
—
5
0
907
9095
—
12
7
861
8758
18
23
724
7361
Outpatient Visit
OP [9202]
3.6e-01
7.0e-01
8.8e-01
5.2e+00
1.3e+00
9.6e-01
8.4e-01
cases:78.40%
controls:71.59%
cases:66.23%
controls:49.41%
cases:22.37%
controls:10.65%
cases:52.96%
controls:0.60%
cases:29.23%
controls:10.10%
cases:71.59%
controls:49.21%
cases:89.22%
controls:78.20%
715
6511
197
2584
604
4494
308
4601
204
969
708
8126
483
55
429
9040
266
916
644
8151
625
4313
248
4452
662
5774
80
1610
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
4.3e-01
1.9e+00
4.0e+00
—
1.9e+00
1.4e+00
7.5e-01
cases:3.84%
controls:2.53%
cases:8.33%
controls:1.41%
cases:8.33%
controls:0.16%
—
—
cases:1.43%
controls:0.22%
cases:6.30%
controls:1.61%
cases:8.89%
controls:4.40%
35
230
877
8865
76
128
836
8967
76
15
836
9080
—
13
20
897
9047
55
141
818
8624
66
325
676
7059
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
7.8e-01
1.7e+00
3.7e+00
—
1.4e+00
1.1e+00
9.0e-01
cases:9.10%
controls:4.40%
cases:13.16%
controls:2.57%
cases:13.38%
controls:0.36%
—
—
cases:1.65%
controls:0.41%
cases:7.90%
controls:2.65%
cases:14.56%
controls:6.46%
83
400
829
8695
120
234
792
8861
122
33
790
9062
—
15
37
895
9030
69
232
804
8533
108
477
634
6907
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
5.4e-01
1.8e+00
3.9e+00
—
1.9e+00
1.4e+00
6.9e-01
cases:4.82%
controls:2.87%
cases:8.44%
controls:1.52%
cases:8.22%
controls:0.19%
—
—
cases:1.43%
controls:0.22%
cases:6.76%
controls:1.73%
cases:9.03%
controls:4.73%
44
261
868
8834
77
138
835
8957
75
17
837
9078
—
13
20
897
9047
59
152
814
8613
67
349
675
7035
empagliflozin; oral
A10BK03 [1123740]
1.5e+00
1.7e+00
1.9e+00
—
1.8e+00
1.6e+00
1.1e+00
cases:5.92%
controls:1.43%
cases:6.80%
controls:1.29%
cases:2.85%
controls:0.44%
—
—
cases:2.20%
controls:0.37%
cases:7.10%
controls:1.59%
cases:7.82%
controls:2.71%
54
130
858
8965
62
117
850
8978
26
40
886
9055
—
20
34
890
9033
62
139
811
8626
58
200
684
7184
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
9.4e-01
1.4e+00
2.5e+00
—
2.3e+00
1.1e+00
1.0e+00
cases:5.26%
controls:2.13%
cases:3.07%
controls:0.76%
cases:0.66%
controls:0.05%
—
—
cases:0.88%
controls:0.09%
cases:2.75%
controls:0.90%
cases:5.66%
controls:2.15%
48
194
864
8901
28
69
884
9026
6
5
906
9090
—
8
8
902
9059
24
79
849
8686
42
159
700
7225
Supplier / Service Provider
OMOP5117446 [33004]
-5.0e-01
-3.4e-01
8.7e-01
-1.0e+50
3.0e+00
2.9e+00
2.9e+00
cases:19.63%
controls:28.75%
cases:6.91%
controls:9.48%
cases:2.19%
controls:0.93%
cases:0.00%
controls:0.05%
cases:1.54%
controls:0.08%
cases:8.02%
controls:0.46%
cases:18.33%
controls:1.16%
179
2615
733
6480
63
862
849
8233
20
85
892
9010
0
5
912
9090
14
7
896
9060
70
40
803
8725
136
86
606
7298
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
3.2e-01
1.7e+00
4.6e+00
1.0e+50
—
2.1e+00
7.1e-01
cases:1.54%
controls:1.12%
cases:2.63%
controls:0.47%
cases:7.24%
controls:0.08%
cases:1.43%
controls:0.00%
—
—
cases:3.78%
controls:0.50%
cases:4.31%
controls:2.17%
14
102
898
8993
24
43
888
9052
66
7
846
9088
13
0
899
9095
—
33
44
840
8721
32
160
710
7224
tibolone; oral
G03CX01 [21602536]
2.1e+00
2.6e+00
—
—
—
2.5e+00
1.8e+00
cases:2.74%
controls:0.35%
cases:2.96%
controls:0.23%
—
—
—
—
—
—
cases:2.63%
controls:0.23%
cases:2.29%
controls:0.38%
25
32
887
9063
27
21
885
9074
—
—
—
23
20
850
8745
17
28
725
7356
Cardiology
6 [38004451]
3.8e-01
5.3e-01
1.4e+00
3.4e+00
1.4e+00
9.9e-01
5.9e-01
cases:15.57%
controls:11.17%
cases:9.32%
controls:5.68%
cases:3.07%
controls:0.80%
cases:1.64%
controls:0.05%
cases:3.41%
controls:0.86%
cases:13.17%
controls:5.33%
cases:20.62%
controls:12.64%
142
1016
770
8079
85
517
827
8578
28
73
884
9022
15
5
897
9090
31
78
879
8989
115
467
758
8298
153
933
589
6451
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.6e-01
8.1e-01
2.2e+00
3.3e+00
9.5e-01
6.5e-01
4.9e-01
cases:32.35%
controls:26.98%
cases:38.38%
controls:21.75%
cases:29.61%
controls:4.51%
cases:4.93%
controls:0.19%
cases:11.43%
controls:4.73%
cases:35.85%
controls:22.56%
cases:49.46%
controls:37.53%
295
2454
617
6641
350
1978
562
7117
270
410
642
8685
45
17
867
9078
104
429
806
8638
313
1977
560
6788
367
2771
375
4613
Differential panel, method unspecified - Blood
69738-3 [42870588]
5.5e-01
1.5e+00
3.3e+00
—
1.4e+00
1.2e+00
7.1e-01
cases:12.72%
controls:7.76%
cases:19.19%
controls:4.95%
cases:20.07%
controls:0.95%
—
—
cases:3.30%
controls:0.86%
cases:14.20%
controls:4.79%
cases:18.46%
controls:10.06%
116
706
796
8389
175
450
737
8645
183
86
729
9009
—
30
78
880
8989
124
420
749
8345
137
743
605
6641
Monocytes [#/volume] in Blood
26484-6 [3001604]
3.9e-01
1.5e+00
3.3e+00
—
1.3e+00
1.1e+00
7.5e-01
cases:16.67%
controls:11.91%
cases:26.75%
controls:7.42%
cases:27.96%
controls:1.41%
—
—
cases:4.84%
controls:1.31%
cases:18.44%
controls:7.07%
cases:28.84%
controls:16.03%
152
1083
760
8012
244
675
668
8420
255
128
657
8967
—
44
119
866
8948
161
620
712
8145
214
1184
528
6200
Basophils [#/volume] in Blood
26444-0 [3006315]
4.0e-01
1.5e+00
3.3e+00
—
1.3e+00
1.1e+00
7.3e-01
cases:16.78%
controls:11.95%
cases:26.75%
controls:7.48%
cases:27.96%
controls:1.43%
—
—
cases:4.84%
controls:1.32%
cases:18.56%
controls:7.12%
cases:28.44%
controls:16.10%
153
1087
759
8008
244
680
668
8415
255
130
657
8965
—
44
120
866
8947
162
624
711
8141
211
1189
531
6195
Abdominal ultrasound examination
JN3AE [2001305555]
5.7e-01
1.2e+00
2.5e+00
1.0e+50
2.9e+00
1.8e+00
6.9e-01
cases:2.85%
controls:1.63%
cases:1.43%
controls:0.45%
cases:0.66%
controls:0.05%
cases:3.40%
controls:0.00%
cases:1.21%
controls:0.07%
cases:3.32%
controls:0.59%
cases:3.23%
controls:1.65%
26
148
886
8947
13
41
899
9054
6
5
906
9090
31
0
881
9095
11
6
899
9061
29
52
844
8713
24
122
718
7262
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.7e-01
1.5e+00
3.2e+00
—
1.4e+00
1.1e+00
6.8e-01
cases:15.79%
controls:11.47%
cases:25.22%
controls:6.95%
cases:25.77%
controls:1.34%
—
—
cases:4.73%
controls:1.25%
cases:17.87%
controls:6.78%
cases:25.61%
controls:14.80%
144
1043
768
8052
230
632
682
8463
235
122
677
8973
—
43
113
867
8954
156
594
717
8171
190
1093
552
6291
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
6.9e-01
1.3e+00
2.0e+00
—
1.9e+00
1.4e+00
9.1e-01
cases:3.40%
controls:1.74%
cases:2.96%
controls:0.85%
cases:1.10%
controls:0.14%
—
—
cases:0.77%
controls:0.11%
cases:2.75%
controls:0.70%
cases:5.39%
controls:2.23%
31
158
881
8937
27
77
885
9018
10
13
902
9082
—
7
10
903
9057
24
61
849
8704
40
165
702
7219
Emergency Room Visit
ER [9203]
4.8e-01
5.7e-01
9.7e-01
4.0e+00
9.9e-01
5.9e-01
6.5e-01
cases:43.20%
controls:31.91%
cases:17.21%
controls:10.56%
cases:3.29%
controls:1.28%
cases:4.06%
controls:0.08%
cases:3.63%
controls:1.38%
cases:16.38%
controls:9.75%
cases:40.84%
controls:26.48%
394
2902
518
6193
157
960
755
8135
30
116
882
8979
37
7
875
9088
33
125
877
8942
143
855
730
7910
303
1955
439
5429
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.5e-01
1.5e+00
3.2e+00
—
1.4e+00
1.1e+00
6.7e-01
cases:15.57%
controls:11.47%
cases:25.00%
controls:6.93%
cases:25.77%
controls:1.34%
—
—
cases:4.73%
controls:1.25%
cases:17.87%
controls:6.74%
cases:25.34%
controls:14.76%
142
1043
770
8052
228
630
684
8465
235
122
677
8973
—
43
113
867
8954
156
591
717
8174
188
1090
554
6294
Eosinophils [#/volume] in Blood
26449-9 [3013115]
3.9e-01
1.5e+00
3.2e+00
—
1.3e+00
1.1e+00
7.2e-01
cases:17.65%
controls:12.62%
cases:27.19%
controls:7.81%
cases:28.07%
controls:1.52%
—
—
cases:4.95%
controls:1.37%
cases:18.90%
controls:7.34%
cases:28.98%
controls:16.54%
161
1148
751
7947
248
710
664
8385
256
138
656
8957
—
45
124
865
8943
165
643
708
8122
215
1221
527
6163
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.5e-01
1.5e+00
3.2e+00
—
1.4e+00
1.1e+00
6.7e-01
cases:15.46%
controls:11.43%
cases:24.78%
controls:6.88%
cases:25.88%
controls:1.34%
—
—
cases:4.73%
controls:1.26%
cases:17.75%
controls:6.72%
cases:25.20%
controls:14.75%
141
1040
771
8055
226
626
686
8469
236
122
676
8973
—
43
114
867
8953
155
589
718
8176
187
1089
555
6295
Carbon dioxide [Partial pressure] in Blood
11557-6 [3013290]
1.8e+00
2.1e+00
—
—
—
2.5e+00
1.8e+00
cases:2.30%
controls:0.41%
cases:1.64%
controls:0.20%
—
—
—
—
—
—
cases:1.83%
controls:0.16%
cases:2.02%
controls:0.33%
21
37
891
9058
15
18
897
9077
—
—
—
16
14
857
8751
15
24
727
7360
Base excess in Blood by calculation
11555-0 [3012501]
1.8e+00
2.1e+00
—
—
—
2.5e+00
1.8e+00
cases:2.30%
controls:0.41%
cases:1.64%
controls:0.20%
—
—
—
—
—
—
cases:1.83%
controls:0.16%
cases:2.02%
controls:0.33%
21
37
891
9058
15
18
897
9077
—
—
—
16
14
857
8751
15
24
727
7360
Oxygen [Partial pressure] in Blood
11556-8 [3027315]
1.8e+00
2.1e+00
—
—
—
2.5e+00
1.8e+00
cases:2.30%
controls:0.41%
cases:1.64%
controls:0.20%
—
—
—
—
—
—
cases:1.83%
controls:0.16%
cases:2.02%
controls:0.34%
21
37
891
9058
15
18
897
9077
—
—
—
16
14
857
8751
15
25
727
7359
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.3e-01
1.5e+00
3.2e+00
—
1.3e+00
1.1e+00
6.8e-01
cases:15.68%
controls:11.78%
cases:25.44%
controls:7.23%
cases:25.66%
controls:1.39%
—
—
cases:4.73%
controls:1.33%
cases:17.98%
controls:7.06%
cases:26.15%
controls:15.20%
143
1071
769
8024
232
658
680
8437
234
126
678
8969
—
43
121
867
8946
157
619
716
8146
194
1122
548
6262
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
8.9e-01
1.5e+00
3.6e+00
—
—
1.2e+00
8.5e-01
cases:2.41%
controls:1.00%
cases:2.63%
controls:0.63%
cases:3.07%
controls:0.09%
—
—
—
—
cases:2.75%
controls:0.83%
cases:5.39%
controls:2.37%
22
91
890
9004
24
57
888
9038
28
8
884
9087
—
—
24
73
849
8692
40
175
702
7209
Other specified special examinations
Z01.8 [45581003]
1.2e-01
1.1e+00
2.3e+00
—
2.4e+00
1.5e+00
6.9e-01
cases:2.74%
controls:2.44%
cases:2.74%
controls:0.96%
cases:1.32%
controls:0.13%
—
—
cases:0.99%
controls:0.09%
cases:3.67%
controls:0.86%
cases:5.93%
controls:3.06%
25
222
887
8873
25
87
887
9008
12
12
900
9083
—
9
8
901
9059
32
75
841
8690
44
226
698
7158
hydroxycarbamide; oral
L01XX05 [21603787]
2.1e+00
2.2e+00
—
—
—
3.0e+00
2.8e+00
cases:0.55%
controls:0.07%
cases:0.66%
controls:0.08%
—
—
—
—
—
—
cases:1.72%
controls:0.09%
cases:2.16%
controls:0.14%
5
6
907
9089
6
7
906
9088
—
—
—
15
8
858
8757
16
10
726
7374
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
3.8e-01
1.5e+00
3.2e+00
1.0e+50
1.5e+00
8.0e-01
4.6e-01
cases:11.40%
controls:8.06%
cases:17.00%
controls:4.44%
cases:11.84%
controls:0.54%
cases:0.55%
controls:0.00%
cases:2.75%
controls:0.61%
cases:10.31%
controls:4.93%
cases:20.62%
controls:14.10%
104
733
808
8362
155
404
757
8691
108
49
804
9046
5
0
907
9095
25
55
885
9012
90
432
783
8333
153
1041
589
6343
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
1.4e+00
1.4e+00
2.3e+00
—
1.3e+00
1.8e+00
9.6e-01
cases:7.79%
controls:2.11%
cases:5.04%
controls:1.31%
cases:1.86%
controls:0.19%
—
—
cases:0.55%
controls:0.14%
cases:6.64%
controls:1.13%
cases:8.89%
controls:3.59%
71
192
841
8903
46
119
866
8976
17
17
895
9078
—
5
13
905
9054
58
99
815
8666
66
265
676
7119
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.1e-01
1.5e+00
3.3e+00
—
1.3e+00
1.0e+00
7.0e-01
cases:16.34%
controls:12.49%
cases:26.64%
controls:7.78%
cases:28.07%
controls:1.47%
—
—
cases:4.73%
controls:1.40%
cases:18.44%
controls:7.37%
cases:28.57%
controls:16.54%
149
1136
763
7959
243
708
669
8387
256
134
656
8961
—
43
127
867
8940
161
646
712
8119
212
1221
530
6163
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.9e-01
7.5e-01
1.8e+00
3.0e+00
9.4e-01
4.2e-01
4.3e-01
cases:43.42%
controls:36.57%
cases:45.18%
controls:27.94%
cases:23.79%
controls:5.06%
cases:3.95%
controls:0.20%
cases:12.09%
controls:5.10%
cases:38.37%
controls:29.05%
cases:58.89%
controls:48.29%
396
3326
516
5769
412
2541
500
6554
217
460
695
8635
36
18
876
9077
110
462
800
8605
335
2546
538
6219
437
3566
305
3818
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.8e-01
7.5e-01
1.7e+00
3.1e+00
9.4e-01
4.1e-01
4.3e-01
cases:42.98%
controls:36.21%
cases:44.63%
controls:27.55%
cases:23.25%
controls:5.00%
cases:4.06%
controls:0.20%
cases:11.76%
controls:4.95%
cases:37.57%
controls:28.60%
cases:58.76%
controls:48.06%
392
3293
520
5802
407
2506
505
6589
212
455
700
8640
37
18
875
9077
107
449
803
8618
328
2507
545
6258
436
3549
306
3835
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.2e-01
7.4e-01
1.8e+00
3.1e+00
9.2e-01
4.6e-01
5.2e-01
cases:32.35%
controls:27.75%
cases:38.38%
controls:22.84%
cases:22.15%
controls:4.52%
cases:3.40%
controls:0.15%
cases:9.78%
controls:4.12%
cases:33.79%
controls:24.29%
cases:54.18%
controls:41.20%
295
2524
617
6571
350
2077
562
7018
202
411
710
8684
31
14
881
9081
89
374
821
8693
295
2129
578
6636
402
3042
340
4342
Platelets [#/volume] in Blood
26515-7 [3007461]
1.8e-01
7.8e-01
2.2e+00
3.1e+00
9.4e-01
5.3e-01
2.2e-01
cases:47.48%
controls:43.07%
cases:54.17%
controls:35.24%
cases:40.46%
controls:7.25%
cases:6.80%
controls:0.33%
cases:17.14%
controls:7.46%
cases:49.14%
controls:36.24%
cases:61.73%
controls:56.34%
433
3917
479
5178
494
3205
418
5890
369
659
543
8436
62
30
850
9065
156
676
754
8391
429
3176
444
5589
458
4160
284
3224
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.7e-01
7.7e-01
2.2e+00
3.1e+00
9.4e-01
5.3e-01
2.2e-01
cases:47.48%
controls:43.17%
cases:54.28%
controls:35.36%
cases:40.46%
controls:7.27%
cases:6.80%
controls:0.33%
cases:17.25%
controls:7.50%
cases:49.14%
controls:36.29%
cases:61.86%
controls:56.43%
433
3926
479
5169
495
3216
417
5879
369
661
543
8434
62
30
850
9065
157
680
753
8387
429
3181
444
5584
459
4167
283
3217
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.7e-01
7.7e-01
2.2e+00
3.1e+00
9.5e-01
5.3e-01
2.2e-01
cases:47.37%
controls:43.20%
cases:54.28%
controls:35.40%
cases:40.46%
controls:7.29%
cases:6.80%
controls:0.33%
cases:17.36%
controls:7.51%
cases:49.14%
controls:36.36%
cases:61.86%
controls:56.49%
432
3929
480
5166
495
3220
417
5875
369
663
543
8432
62
30
850
9065
158
681
752
8386
429
3187
444
5578
459
4171
283
3213
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.7e-01
7.8e-01
2.2e+00
3.1e+00
9.4e-01
5.2e-01
2.2e-01
cases:47.48%
controls:43.22%
cases:54.39%
controls:35.37%
cases:40.46%
controls:7.27%
cases:6.80%
controls:0.33%
cases:17.25%
controls:7.50%
cases:49.03%
controls:36.35%
cases:61.86%
controls:56.46%
433
3931
479
5164
496
3217
416
5878
369
661
543
8434
62
30
850
9065
157
680
753
8387
428
3186
445
5579
459
4169
283
3215
MCH [Entitic mass]
28539-5 [3035941]
1.8e-01
7.6e-01
2.2e+00
3.1e+00
9.6e-01
5.3e-01
2.2e-01
cases:47.48%
controls:43.09%
cases:53.95%
controls:35.28%
cases:40.35%
controls:7.27%
cases:6.80%
controls:0.33%
cases:17.36%
controls:7.46%
cases:49.03%
controls:36.26%
cases:61.86%
controls:56.43%
433
3919
479
5176
492
3209
420
5886
368
661
544
8434
62
30
850
9065
158
676
752
8391
428
3178
445
5587
459
4167
283
3217
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.7e-01
7.7e-01
2.2e+00
3.1e+00
9.4e-01
5.3e-01
2.2e-01
cases:47.48%
controls:43.14%
cases:54.17%
controls:35.36%
cases:40.46%
controls:7.27%
cases:6.80%
controls:0.33%
cases:17.25%
controls:7.50%
cases:49.14%
controls:36.31%
cases:61.86%
controls:56.45%
433
3924
479
5171
494
3216
418
5879
369
661
543
8434
62
30
850
9065
157
680
753
8387
429
3183
444
5582
459
4168
283
3216
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.7e-01
7.7e-01
2.2e+00
3.1e+00
9.5e-01
5.2e-01
2.3e-01
cases:47.48%
controls:43.14%
cases:54.06%
controls:35.35%
cases:40.46%
controls:7.27%
cases:6.80%
controls:0.33%
cases:17.25%
controls:7.48%
cases:49.03%
controls:36.29%
cases:61.86%
controls:56.42%
433
3924
479
5171
493
3215
419
5880
369
661
543
8434
62
30
850
9065
157
678
753
8389
428
3181
445
5584
459
4166
283
3218
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
3.2e-01
1.4e+00
3.2e+00
—
1.2e+00
9.9e-01
6.4e-01
cases:15.24%
controls:11.52%
cases:24.01%
controls:7.04%
cases:25.00%
controls:1.36%
—
—
cases:4.07%
controls:1.27%
cases:16.72%
controls:6.95%
cases:25.07%
controls:14.95%
139
1048
773
8047
219
640
693
8455
228
124
684
8971
—
37
115
873
8952
146
609
727
8156
186
1104
556
6280
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.7e-01
6.4e-01
1.9e+00
2.8e+00
1.1e+00
4.3e-01
6.2e-01
cases:13.49%
controls:9.71%
cases:9.32%
controls:5.16%
cases:5.04%
controls:0.76%
cases:0.88%
controls:0.05%
cases:2.31%
controls:0.79%
cases:7.90%
controls:5.31%
cases:21.43%
controls:12.81%
123
883
789
8212
85
469
827
8626
46
69
866
9026
8
5
904
9090
21
72
889
8995
69
465
804
8300
159
946
583
6438
INR in Blood by Coagulation assay
34714-6 [3032080]
4.1e-01
6.2e-01
1.0e+00
2.8e+00
1.1e+00
7.0e-01
6.5e-01
cases:15.79%
controls:11.03%
cases:11.40%
controls:6.47%
cases:5.59%
controls:2.08%
cases:1.64%
controls:0.10%
cases:5.16%
controls:1.86%
cases:12.03%
controls:6.35%
cases:23.72%
controls:14.00%
144
1003
768
8092
104
588
808
8507
51
189
861
8906
15
9
897
9086
47
169
863
8898
105
557
768
8208
176
1034
566
6350
Pulmonary Disease
29 [38004472]
6.9e-01
8.9e-01
1.3e+00
—
1.5e+00
1.6e+00
1.3e+00
cases:18.53%
controls:10.25%
cases:12.39%
controls:5.49%
cases:3.62%
controls:1.00%
—
—
cases:4.29%
controls:1.00%
cases:21.08%
controls:5.10%
cases:31.67%
controls:11.24%
169
932
743
8163
113
499
799
8596
33
91
879
9004
—
39
91
871
8976
184
447
689
8318
235
830
507
6554
CBC panel - Blood by Automated count
58410-2 [40761511]
2.6e-01
6.9e-01
1.5e+00
3.0e+00
9.5e-01
5.2e-01
2.7e-01
cases:42.11%
controls:36.03%
cases:38.27%
controls:23.71%
cases:16.23%
controls:3.96%
cases:4.06%
controls:0.21%
cases:10.66%
controls:4.41%
cases:34.36%
controls:23.72%
cases:50.94%
controls:44.20%
384
3277
528
5818
349
2156
563
6939
148
360
764
8735
37
19
875
9076
97
400
813
8667
300
2079
573
6686
378
3264
364
4120
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
6.0e-01
1.8e+00
2.2e+00
—
—
1.7e+00
1.5e+00
cases:1.32%
controls:0.73%
cases:1.43%
controls:0.23%
cases:0.77%
controls:0.09%
—
—
—
—
cases:1.60%
controls:0.30%
cases:2.70%
controls:0.60%
12
66
900
9029
13
21
899
9074
7
8
905
9087
—
—
14
26
859
8739
20
44
722
7340
pH of Blood
11558-4 [3010421]
1.6e+00
2.0e+00
—
—
—
2.1e+00
1.5e+00
cases:2.41%
controls:0.48%
cases:1.75%
controls:0.24%
—
—
—
—
—
—
cases:2.06%
controls:0.26%
cases:2.70%
controls:0.64%
22
44
890
9051
16
22
896
9073
—
—
—
18
23
855
8742
20
47
722
7337
pH of Capillary blood
2745-8 [3009343]
8.6e-01
9.0e-01
2.4e+00
—
2.2e+00
1.3e+00
1.3e+00
cases:2.08%
controls:0.89%
cases:1.21%
controls:0.49%
cases:0.99%
controls:0.09%
—
—
cases:0.66%
controls:0.08%
cases:2.18%
controls:0.59%
cases:5.39%
controls:1.60%
19
81
893
9014
11
45
901
9050
9
8
903
9087
—
6
7
904
9060
19
52
854
8713
40
118
702
7266
Bone marrow biopsy
XW000 [2001310618]
1.4e+00
2.7e+00
—
1.0e+50
—
3.0e+00
1.4e+00
cases:0.77%
controls:0.19%
cases:1.75%
controls:0.12%
—
—
cases:4.39%
controls:0.00%
—
—
cases:2.06%
controls:0.10%
cases:1.62%
controls:0.39%
7
17
905
9078
16
11
896
9084
—
40
0
872
9095
—
18
9
855
8756
12
29
730
7355
Gas panel - Central venous blood
97535-9 [1616796]
1.7e+00
1.6e+00
—
—
—
1.8e+00
2.0e+00
cases:1.86%
controls:0.36%
cases:1.32%
controls:0.26%
—
—
—
—
—
—
cases:1.60%
controls:0.26%
cases:3.10%
controls:0.42%
17
33
895
9062
12
24
900
9071
—
—
—
14
23
859
8742
23
31
719
7353
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
8.3e-01
8.1e-01
2.3e+00
—
2.2e+00
1.3e+00
1.3e+00
cases:2.08%
controls:0.92%
cases:1.21%
controls:0.54%
cases:0.99%
controls:0.10%
—
—
cases:0.66%
controls:0.08%
cases:2.18%
controls:0.60%
cases:5.80%
controls:1.64%
19
84
893
9011
11
49
901
9046
9
9
903
9086
—
6
7
904
9060
19
53
854
8712
43
121
699
7263
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.0e-01
7.1e-01
1.7e+00
3.0e+00
8.5e-01
3.7e-01
3.0e-01
cases:45.29%
controls:40.30%
cases:49.67%
controls:32.64%
cases:27.63%
controls:6.30%
cases:4.50%
controls:0.24%
cases:13.52%
controls:6.28%
cases:42.27%
controls:33.54%
cases:60.78%
controls:53.41%
413
3665
499
5430
453
2969
459
6126
252
573
660
8522
41
22
871
9073
123
569
787
8498
369
2940
504
5825
451
3944
291
3440
Blasts/Leukocytes in Blood
26446-5 [3025159]
6.2e-01
1.3e+00
3.5e+00
—
—
1.2e+00
9.1e-01
cases:1.86%
controls:1.01%
cases:2.63%
controls:0.71%
cases:3.29%
controls:0.10%
—
—
—
—
cases:2.75%
controls:0.88%
cases:5.80%
controls:2.42%
17
92
895
9003
24
65
888
9030
30
9
882
9086
—
—
24
77
849
8688
43
179
699
7205
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
2.7e-01
5.4e-01
1.8e+00
2.9e+00
1.1e+00
4.0e-01
5.2e-01
cases:13.49%
controls:10.64%
cases:9.87%
controls:5.97%
cases:5.92%
controls:0.99%
cases:0.99%
controls:0.05%
cases:2.64%
controls:0.90%
cases:8.59%
controls:5.93%
cases:23.05%
controls:15.13%
123
968
789
8127
90
543
822
8552
54
90
858
9005
9
5
903
9090
24
82
886
8985
75
520
798
8245
171
1117
571
6267
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.1e+00
1.1e+00
2.5e+00
—
1.2e+00
1.1e+00
1.1e+00
cases:3.95%
controls:1.40%
cases:2.52%
controls:0.81%
cases:1.64%
controls:0.14%
—
—
cases:0.55%
controls:0.17%
cases:2.29%
controls:0.80%
cases:5.12%
controls:1.69%
36
127
876
8968
23
74
889
9021
15
13
897
9082
—
5
15
905
9052
20
70
853
8695
38
125
704
7259
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.4e-01
5.7e-01
1.6e+00
2.8e+00
8.0e-01
4.5e-01
3.5e-01
cases:38.16%
controls:32.71%
cases:31.58%
controls:20.77%
cases:16.78%
controls:3.82%
cases:2.96%
controls:0.19%
cases:8.24%
controls:3.89%
cases:28.98%
controls:20.64%
cases:50.13%
controls:41.50%
348
2975
564
6120
288
1889
624
7206
153
347
759
8748
27
17
885
9078
75
353
835
8714
253
1809
620
6956
372
3064
370
4320
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
6.9e-01
1.3e+00
3.3e+00
—
—
1.2e+00
9.0e-01
cases:2.19%
controls:1.11%
cases:2.63%
controls:0.70%
cases:3.07%
controls:0.12%
—
—
—
—
cases:2.75%
controls:0.87%
cases:5.80%
controls:2.44%
20
101
892
8994
24
64
888
9031
28
11
884
9084
—
—
24
76
849
8689
43
180
699
7204
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.4e-01
7.3e-01
1.8e+00
2.8e+00
5.1e-01
3.4e-01
3.1e-01
cases:43.42%
controls:37.74%
cases:45.29%
controls:28.46%
cases:23.57%
controls:5.07%
cases:2.41%
controls:0.15%
cases:7.69%
controls:4.76%
cases:37.00%
controls:29.55%
cases:58.89%
controls:51.22%
396
3432
516
5663
413
2588
499
6507
215
461
697
8634
22
14
890
9081
70
432
840
8635
323
2590
550
6175
437
3782
305
3602
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
7.3e-01
1.3e+00
3.3e+00
—
—
1.1e+00
9.3e-01
cases:2.41%
controls:1.18%
cases:2.63%
controls:0.74%
cases:3.18%
controls:0.12%
—
—
—
—
cases:2.75%
controls:0.92%
cases:6.20%
controls:2.53%
22
107
890
8988
24
67
888
9028
29
11
883
9084
—
—
24
81
849
8684
46
187
696
7197
Heart failure, unspecified
I50.9 [45576879]
8.8e-01
1.1e+00
2.5e+00
1.0e+50
1.6e+00
1.1e+00
8.7e-01
cases:3.73%
controls:1.58%
cases:2.30%
controls:0.75%
cases:1.10%
controls:0.09%
cases:0.77%
controls:0.00%
cases:0.77%
controls:0.15%
cases:2.75%
controls:0.91%
cases:6.06%
controls:2.64%
34
144
878
8951
21
68
891
9027
10
8
902
9087
7
0
905
9095
7
14
903
9053
24
80
849
8685
45
195
697
7189
Lactate [Moles/volume] in Capillary blood
19239-3 [3028271]
1.1e+00
2.8e+00
—
—
—
2.0e+00
1.7e+00
cases:0.55%
controls:0.19%
cases:0.88%
controls:0.05%
—
—
—
—
—
—
cases:0.92%
controls:0.13%
cases:1.89%
controls:0.35%
5
17
907
9078
8
5
904
9090
—
—
—
8
11
865
8754
14
26
728
7358
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
3.9e-01
7.7e-01
1.9e+00
—
1.8e+00
1.2e+00
7.9e-01
cases:6.47%
controls:4.49%
cases:4.39%
controls:2.08%
cases:1.64%
controls:0.25%
—
—
cases:1.65%
controls:0.28%
cases:5.04%
controls:1.59%
cases:10.51%
controls:5.07%
59
408
853
8687
40
189
872
8906
15
23
897
9072
—
15
25
895
9042
44
139
829
8626
78
374
664
7010
Laboratory Visit
OMOP4822461 [32036]
8.7e-02
4.8e-01
1.7e+00
2.8e+00
9.6e-01
3.7e-01
1.2e-01
cases:50.22%
controls:48.04%
cases:56.36%
controls:44.40%
cases:46.49%
controls:13.28%
cases:10.86%
controls:0.73%
cases:28.02%
controls:13.00%
cases:54.64%
controls:45.41%
cases:64.02%
controls:61.13%
458
4369
454
4726
514
4038
398
5057
424
1208
488
7887
99
66
813
9029
255
1179
655
7888
477
3980
396
4785
475
4514
267
2870
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
1.5e+00
1.6e+00
—
—
—
2.1e+00
1.1e+00
cases:2.96%
controls:0.66%
cases:1.10%
controls:0.23%
—
—
—
—
—
—
cases:1.95%
controls:0.25%
cases:2.02%
controls:0.65%
27
60
885
9035
10
21
902
9074
—
—
—
17
22
856
8743
15
48
727
7336
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.8e-01
6.6e-01
2.4e+00
—
1.3e+00
8.2e-01
7.4e-01
cases:16.34%
controls:11.73%
cases:11.95%
controls:6.58%
cases:12.83%
controls:1.36%
—
—
cases:3.63%
controls:0.98%
cases:13.86%
controls:6.61%
cases:26.95%
controls:14.95%
149
1067
763
8028
109
598
803
8497
117
124
795
8971
—
33
89
877
8978
121
579
752
8186
200
1104
542
6280
Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]
1.5e+00
1.9e+00
—
—
—
1.7e+00
1.2e+00
cases:2.63%
controls:0.62%
cases:0.99%
controls:0.15%
—
—
—
—
—
—
cases:1.15%
controls:0.21%
cases:2.43%
controls:0.72%
24
56
888
9039
9
14
903
9081
—
—
—
10
18
863
8747
18
53
724
7331
FEV1 percent change
69983-5 [42868472]
4.6e-01
4.6e-01
—
—
2.6e+00
1.8e+00
1.8e+00
cases:2.96%
controls:1.89%
cases:0.99%
controls:0.63%
—
—
—
—
cases:0.77%
controls:0.06%
cases:2.52%
controls:0.41%
cases:5.93%
controls:1.03%
27
172
885
8923
9
57
903
9038
—
—
7
5
903
9062
22
36
851
8729
44
76
698
7308
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
4.6e-01
4.6e-01
—
—
2.6e+00
1.8e+00
1.8e+00
cases:2.96%
controls:1.89%
cases:0.99%
controls:0.63%
—
—
—
—
cases:0.77%
controls:0.06%
cases:2.52%
controls:0.41%
cases:5.93%
controls:1.03%
27
172
885
8923
9
57
903
9038
—
—
7
5
903
9062
22
36
851
8729
44
76
698
7308
FEV1/FVC --post bronchodilation
69970-2 [42868459]
4.6e-01
4.6e-01
—
—
2.6e+00
1.8e+00
1.8e+00
cases:2.96%
controls:1.89%
cases:0.99%
controls:0.63%
—
—
—
—
cases:0.77%
controls:0.06%
cases:2.52%
controls:0.41%
cases:5.93%
controls:1.03%
27
172
885
8923
9
57
903
9038
—
—
7
5
903
9062
22
36
851
8729
44
76
698
7308
FVC percent change Respiratory system
69982-7 [42868471]
4.6e-01
4.6e-01
—
—
2.6e+00
1.8e+00
1.8e+00
cases:2.96%
controls:1.89%
cases:0.99%
controls:0.63%
—
—
—
—
cases:0.77%
controls:0.06%
cases:2.52%
controls:0.41%
cases:5.93%
controls:1.03%
27
172
885
8923
9
57
903
9038
—
—
7
5
903
9062
22
36
851
8729
44
76
698
7308
FEV1 --post bronchodilation
20155-8 [3023550]
4.6e-01
4.6e-01
—
—
2.6e+00
1.8e+00
1.8e+00
cases:2.96%
controls:1.89%
cases:0.99%
controls:0.63%
—
—
—
—
cases:0.77%
controls:0.06%
cases:2.52%
controls:0.41%
cases:5.93%
controls:1.03%
27
172
885
8923
9
57
903
9038
—
—
7
5
903
9062
22
36
851
8729
44
76
698
7308
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-3.1e-03
5.1e-01
1.8e+00
2.8e+00
8.2e-01
3.1e-01
2.9e-02
cases:32.57%
controls:32.63%
cases:35.53%
controls:24.84%
cases:23.79%
controls:4.99%
cases:3.62%
controls:0.22%
cases:10.55%
controls:4.95%
cases:31.04%
controls:24.77%
cases:42.45%
controls:41.75%
297
2968
615
6127
324
2259
588
6836
217
454
695
8641
33
20
879
9075
96
449
814
8618
271
2171
602
6594
315
3083
427
4301
Atrial fibrillation and flutter
I48 [45596206]
8.9e-01
1.0e+00
1.5e+00
—
1.4e+00
7.5e-01
6.7e-01
cases:12.50%
controls:5.56%
cases:8.11%
controls:3.07%
cases:2.52%
controls:0.59%
—
—
cases:2.42%
controls:0.60%
cases:6.41%
controls:3.15%
cases:12.94%
controls:7.07%
114
506
798
8589
74
279
838
8816
23
54
889
9041
—
22
54
888
9013
56
276
817
8489
96
522
646
6862
pH of Serum or Plasma
2753-2 [3018418]
5.3e-01
8.9e-01
2.2e+00
—
1.3e+00
6.2e-01
7.0e-01
cases:9.76%
controls:5.99%
cases:7.79%
controls:3.36%
cases:4.06%
controls:0.48%
—
—
cases:1.87%
controls:0.52%
cases:5.96%
controls:3.31%
cases:15.50%
controls:8.33%
89
545
823
8550
71
306
841
8789
37
44
875
9051
—
17
47
893
9020
52
290
821
8475
115
615
627
6769
Osmolality of Urine
2695-5 [3026782]
3.0e-01
7.7e-01
1.9e+00
—
1.8e+00
9.5e-01
7.3e-01
cases:6.14%
controls:4.64%
cases:4.17%
controls:1.97%
cases:1.21%
controls:0.19%
—
—
cases:1.32%
controls:0.22%
cases:4.01%
controls:1.59%
cases:8.63%
controls:4.33%
56
422
856
8673
38
179
874
8916
11
17
901
9078
—
12
20
898
9047
35
139
838
8626
64
320
678
7064
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
5.0e-01
5.7e-01
—
—
2.4e+00
1.9e+00
1.7e+00
cases:3.51%
controls:2.16%
cases:1.32%
controls:0.75%
—
—
—
—
cases:0.88%
controls:0.08%
cases:2.98%
controls:0.46%
cases:6.33%
controls:1.16%
32
196
880
8899
12
68
900
9027
—
—
8
7
902
9060
26
40
847
8725
47
86
695
7298
FEV1/FVC
19926-5 [3011505]
5.0e-01
5.7e-01
—
—
2.4e+00
1.9e+00
1.7e+00
cases:3.51%
controls:2.16%
cases:1.32%
controls:0.75%
—
—
—
—
cases:0.88%
controls:0.08%
cases:2.98%
controls:0.46%
cases:6.33%
controls:1.16%
32
196
880
8899
12
68
900
9027
—
—
8
7
902
9060
26
40
847
8725
47
86
695
7298
FEV1
20150-9 [3024653]
5.0e-01
5.7e-01
—
—
2.4e+00
1.9e+00
1.7e+00
cases:3.51%
controls:2.16%
cases:1.32%
controls:0.75%
—
—
—
—
cases:0.88%
controls:0.08%
cases:2.98%
controls:0.46%
cases:6.33%
controls:1.16%
32
196
880
8899
12
68
900
9027
—
—
8
7
902
9060
26
40
847
8725
47
86
695
7298
olodaterol and tiotropium bromide
R03AL06 [1588644]
2.2e+00
2.3e+00
—
—
—
2.0e+00
1.8e+00
cases:0.66%
controls:0.08%
cases:0.55%
controls:0.05%
—
—
—
—
—
—
cases:0.80%
controls:0.11%
cases:1.08%
controls:0.18%
6
7
906
9088
5
5
907
9090
—
—
—
7
10
866
8755
8
13
734
7371
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
7.4e-01
8.1e-01
1.1e+00
—
1.2e+00
1.1e+00
9.3e-01
cases:11.62%
controls:5.89%
cases:6.69%
controls:3.08%
cases:1.75%
controls:0.62%
—
—
cases:2.31%
controls:0.68%
cases:9.16%
controls:3.37%
cases:18.19%
controls:8.04%
106
536
806
8559
61
280
851
8815
16
56
896
9039
—
21
62
889
9005
80
295
793
8470
135
594
607
6790
Testosterone Free [Moles/volume] in Serum or Plasma by calculation
96559-0 [36032269]
1.8e+00
1.2e+00
—
—
—
2.4e+00
1.6e+00
cases:3.73%
controls:0.62%
cases:1.21%
controls:0.36%
—
—
—
—
—
—
cases:2.18%
controls:0.21%
cases:4.58%
controls:0.98%
34
56
878
9039
11
33
901
9062
—
—
—
19
18
854
8747
34
72
708
7312
Chronic cardiac insufficiency
201 [2001600199]
6.5e-01
2.5e+00
—
—
—
2.0e+00
1.3e+00
cases:0.88%
controls:0.46%
cases:0.77%
controls:0.07%
—
—
—
—
—
—
cases:0.69%
controls:0.09%
cases:1.62%
controls:0.45%
8
42
904
9053
7
6
905
9089
—
—
—
6
8
867
8757
12
33
730
7351
Oxygen content in Capillary blood by calculation
64799-0 [40767503]
8.7e-01
2.2e+00
—
—
—
1.8e+00
1.8e+00
cases:0.55%
controls:0.23%
cases:1.10%
controls:0.12%
—
—
—
—
—
—
cases:1.37%
controls:0.24%
cases:2.56%
controls:0.43%
5
21
907
9074
10
11
902
9084
—
—
—
12
21
861
8744
19
32
723
7352
Dyspnoea
R06.0 [45558449]
8.4e-01
1.3e+00
1.9e+00
—
1.7e+00
1.2e+00
6.2e-01
cases:7.13%
controls:3.22%
cases:3.73%
controls:1.08%
cases:0.77%
controls:0.12%
—
—
cases:0.77%
controls:0.14%
cases:3.78%
controls:1.19%
cases:8.22%
controls:4.59%
65
293
847
8802
34
98
878
8997
7
11
905
9084
—
7
13
903
9054
33
104
840
8661
61
339
681
7045
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1.3e+00
1.5e+00
—
—
—
1.7e+00
1.2e+00
cases:3.07%
controls:0.88%
cases:2.08%
controls:0.47%
—
—
—
—
—
—
cases:2.63%
controls:0.48%
cases:4.31%
controls:1.30%
28
80
884
9015
19
43
893
9052
—
—
—
23
42
850
8723
32
96
710
7288
Malaise and fatigue
R53 [45553741]
6.0e-01
1.2e+00
—
—
2.3e+00
8.2e-01
7.5e-01
cases:4.61%
controls:2.57%
cases:3.73%
controls:1.14%
—
—
—
—
cases:0.77%
controls:0.08%
cases:2.52%
controls:1.13%
cases:8.49%
controls:4.20%
42
234
870
8861
34
104
878
8991
—
—
7
7
903
9060
22
99
851
8666
63
310
679
7074
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
4.6e-01
6.7e-01
1.9e+00
—
1.4e+00
6.9e-01
5.9e-01
cases:7.89%
controls:5.11%
cases:5.70%
controls:2.99%
cases:1.86%
controls:0.30%
—
—
cases:1.43%
controls:0.35%
cases:5.73%
controls:2.95%
cases:15.50%
controls:9.22%
72
465
840
8630
52
272
860
8823
17
27
895
9068
—
13
32
897
9035
50
259
823
8506
115
681
627
6703
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
4.1e-01
7.0e-01
2.0e+00
—
1.5e+00
7.9e-01
6.2e-01
cases:8.66%
controls:5.92%
cases:5.48%
controls:2.79%
cases:2.08%
controls:0.27%
—
—
cases:1.32%
controls:0.30%
cases:5.61%
controls:2.64%
cases:14.42%
controls:8.27%
79
538
833
8557
50
254
862
8841
19
25
893
9070
—
12
27
898
9040
49
231
824
8534
107
611
635
6773
Case Management Agency
251B00000X [38004193]
1.6e-01
3.0e-01
6.1e-01
3.7e+00
7.2e-01
3.1e-01
2.3e-01
cases:69.96%
controls:66.54%
cases:65.57%
controls:58.44%
cases:36.62%
controls:23.90%
cases:37.83%
controls:1.47%
cases:38.57%
controls:23.38%
cases:67.47%
controls:60.33%
cases:83.42%
controls:80.00%
638
6052
274
3043
598
5315
314
3780
334
2174
578
6921
345
134
567
8961
351
2120
559
6947
589
5288
284
3477
619
5907
123
1477
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
2.9e-01
1.1e+00
3.5e+00
—
1.5e+00
5.8e-01
4.3e-01
cases:8.33%
controls:6.36%
cases:8.00%
controls:2.68%
cases:7.79%
controls:0.26%
—
—
cases:0.99%
controls:0.23%
cases:5.15%
controls:2.95%
cases:12.13%
controls:8.23%
76
578
836
8517
73
244
839
8851
71
24
841
9071
—
9
21
901
9046
45
259
828
8506
90
608
652
6776
digoxin; oral, parenteral
C01AA05 [21600234]
1.2e+00
1.5e+00
6.9e-01
—
1.2e+00
1.6e+00
1.4e+00
cases:4.39%
controls:1.35%
cases:4.17%
controls:1.00%
cases:0.55%
controls:0.27%
—
—
cases:1.21%
controls:0.36%
cases:4.81%
controls:1.06%
cases:6.06%
controls:1.58%
40
123
872
8972
38
91
874
9004
5
25
907
9070
—
11
33
899
9034
42
93
831
8672
45
117
697
7267
Bacteria [Presence] in Urine
87829-8 [36304419]
3.7e-01
7.2e-01
1.7e+00
—
1.5e+00
9.5e-01
7.5e-01
cases:8.00%
controls:5.70%
cases:5.59%
controls:2.80%
cases:1.75%
controls:0.34%
—
—
cases:1.65%
controls:0.37%
cases:5.96%
controls:2.38%
cases:13.88%
controls:7.10%
73
518
839
8577
51
255
861
8840
16
31
896
9064
—
15
34
895
9033
52
209
821
8556
103
524
639
6860
Oncology Clinic/Center
261QX0200X [38004268]
-1.8e-01
8.9e-02
2.3e+00
—
2.1e+00
1.1e+00
4.2e-01
cases:4.61%
controls:5.48%
cases:1.64%
controls:1.51%
cases:0.99%
controls:0.10%
—
—
cases:0.88%
controls:0.11%
cases:4.01%
controls:1.32%
cases:7.82%
controls:5.27%
42
498
870
8597
15
137
897
8958
9
9
903
9086
—
8
10
902
9057
35
116
838
8649
58
389
684
6995
Office Visit
OMOP4822458 [581477]
3.6e-01
6.7e-01
1.6e+00
—
1.7e+00
8.0e-01
7.3e-01
cases:10.86%
controls:7.85%
cases:4.06%
controls:2.11%
cases:0.99%
controls:0.20%
—
—
cases:1.32%
controls:0.24%
cases:4.01%
controls:1.85%
cases:10.38%
controls:5.31%
99
714
813
8381
37
192
875
8903
9
18
903
9077
—
12
22
898
9045
35
162
838
8603
77
392
665
6992
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
4.8e-01
8.0e-01
1.4e+00
—
1.5e+00
7.0e-01
5.2e-01
cases:12.50%
controls:8.15%
cases:7.89%
controls:3.72%
cases:1.75%
controls:0.42%
—
—
cases:1.87%
controls:0.41%
cases:7.56%
controls:3.89%
cases:17.92%
controls:11.50%
114
741
798
8354
72
338
840
8757
16
38
896
9057
—
17
37
893
9030
66
341
807
8424
133
849
609
6535
Metabolic syndrome
E66.00 [2000501500]
1.3e+00
1.6e+00
—
1.0e+50
—
1.6e+00
1.0e+00
cases:2.74%
controls:0.74%
cases:1.75%
controls:0.37%
—
—
cases:1.43%
controls:0.00%
—
—
cases:1.72%
controls:0.37%
cases:3.10%
controls:1.14%
25
67
887
9028
16
34
896
9061
—
13
0
899
9095
—
15
32
858
8733
23
84
719
7300
Extreme obesity with alveolar hypoventilation
E66.2 [45581373]
—
—
—
—
—
2.5e+00
2.9e+00
—
—
—
—
—
—
—
—
—
—
cases:0.80%
controls:0.07%
cases:2.02%
controls:0.11%
—
—
—
—
—
7
6
866
8759
15
8
727
7376
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
6.4e-01
6.9e-01
1.7e+00
—
1.9e+00
5.3e-01
5.2e-01
cases:10.75%
controls:5.99%
cases:6.36%
controls:3.31%
cases:2.41%
controls:0.45%
—
—
cases:1.87%
controls:0.30%
cases:5.73%
controls:3.47%
cases:14.15%
controls:8.94%
98
545
814
8550
58
301
854
8794
22
41
890
9054
—
17
27
893
9040
50
304
823
8461
105
660
637
6724
Psychiatry
26 [38004469]
4.6e-01
7.7e-01
9.8e-01
—
1.1e+00
1.1e+00
9.6e-01
cases:8.77%
controls:5.71%
cases:5.70%
controls:2.72%
cases:2.74%
controls:1.04%
—
—
cases:2.97%
controls:1.05%
cases:7.33%
controls:2.52%
cases:11.59%
controls:4.79%
80
519
832
8576
52
247
860
8848
25
95
887
9000
—
27
95
883
8972
64
221
809
8544
86
354
656
7030
Obesity due to excess calories
E66.01 [2000501501]
6.4e-01
1.1e+00
1.9e+00
—
1.4e+00
1.3e+00
1.0e+00
cases:2.19%
controls:1.17%
cases:1.86%
controls:0.65%
cases:0.77%
controls:0.11%
—
—
cases:0.77%
controls:0.19%
cases:2.18%
controls:0.60%
cases:3.91%
controls:1.48%
20
106
892
8989
17
59
895
9036
7
10
905
9085
—
7
17
903
9050
19
53
854
8712
29
109
713
7275
liraglutide; parenteral
A10BJ02 [1123630]
1.3e+00
1.6e+00
1.2e+00
—
1.3e+00
1.2e+00
1.1e+00
cases:2.08%
controls:0.55%
cases:1.97%
controls:0.42%
cases:0.66%
controls:0.20%
—
—
cases:0.66%
controls:0.18%
cases:1.72%
controls:0.50%
cases:2.83%
controls:0.92%
19
50
893
9045
18
38
894
9057
6
18
906
9077
—
6
16
904
9051
15
44
858
8721
21
68
721
7316
Thorax X-ray examination
GD1AA [2001303617]
5.4e-01
9.7e-01
6.0e-01
—
1.9e+00
9.6e-01
8.8e-01
cases:13.93%
controls:8.62%
cases:8.11%
controls:3.24%
cases:0.66%
controls:0.36%
—
—
cases:2.31%
controls:0.34%
cases:8.02%
controls:3.23%
cases:20.35%
controls:9.57%
127
784
785
8311
74
295
838
8800
6
33
906
9062
—
21
31
889
9036
70
283
803
8482
151
707
591
6677
Diabetes non-insulin dependent
T90 [2002001131]
9.2e-01
1.1e+00
1.2e+00
—
8.6e-01
9.9e-01
1.0e+00
cases:14.69%
controls:6.43%
cases:11.51%
controls:4.01%
cases:2.41%
controls:0.76%
—
—
cases:1.98%
controls:0.85%
cases:9.97%
controls:3.95%
cases:20.75%
controls:8.40%
134
585
778
8510
105
365
807
8730
22
69
890
9026
—
18
77
892
8990
87
346
786
8419
154
620
588
6764
tiotropium bromide; inhalant
R03BB04 [21603296]
9.4e-01
9.8e-01
1.1e+00
—
8.6e-01
1.1e+00
1.1e+00
cases:5.04%
controls:2.03%
cases:4.17%
controls:1.61%
cases:1.54%
controls:0.53%
—
—
cases:1.43%
controls:0.61%
cases:5.04%
controls:1.78%
cases:7.41%
controls:2.51%
46
185
866
8910
38
146
874
8949
14
48
898
9047
—
13
55
897
9012
44
156
829
8609
55
185
687
7199
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
2.5e-01
6.7e-01
1.6e+00
—
1.3e+00
9.8e-01
6.9e-01
cases:7.35%
controls:5.83%
cases:5.70%
controls:2.99%
cases:1.75%
controls:0.37%
—
—
cases:1.54%
controls:0.43%
cases:6.41%
controls:2.51%
cases:14.29%
controls:7.71%
67
530
845
8565
52
272
860
8823
16
34
896
9061
—
14
39
896
9028
56
220
817
8545
106
569
636
6815
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.3e-01
7.2e-01
2.1e+00
—
8.8e-01
5.7e-01
5.8e-01
cases:26.86%
controls:20.92%
cases:24.12%
controls:13.42%
cases:18.31%
controls:2.65%
—
—
cases:5.27%
controls:2.26%
cases:21.53%
controls:13.42%
cases:40.16%
controls:27.40%
245
1903
667
7192
220
1221
692
7874
167
241
745
8854
—
48
205
862
8862
188
1176
685
7589
298
2023
444
5361
warfarin; oral, parenteral
B01AA03 [21600965]
7.9e-01
8.6e-01
8.3e-01
—
8.8e-01
1.0e+00
8.1e-01
cases:10.75%
controls:5.20%
cases:9.43%
controls:4.21%
cases:2.52%
controls:1.11%
—
—
cases:2.86%
controls:1.20%
cases:10.88%
controls:4.28%
cases:12.13%
controls:5.80%
98
473
814
8622
86
383
826
8712
23
101
889
8994
—
26
109
884
8958
95
375
778
8390
90
428
652
6956
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.4e-01
6.3e-01
1.9e+00
—
1.1e+00
7.3e-01
4.9e-01
cases:18.09%
controls:13.58%
cases:12.06%
controls:6.82%
cases:5.70%
controls:0.92%
—
—
cases:2.53%
controls:0.84%
cases:12.94%
controls:6.70%
cases:26.82%
controls:18.36%
165
1235
747
7860
110
620
802
8475
52
84
860
9011
—
23
76
887
8991
113
587
760
8178
199
1356
543
6028
Granulocytes [#/volume] in Blood
30394-1 [3035715]
—
2.5e+00
—
—
—
2.7e+00
1.2e+00
—
—
cases:1.32%
controls:0.11%
—
—
—
—
—
—
cases:1.15%
controls:0.08%
cases:0.81%
controls:0.24%
—
12
10
900
9085
—
—
—
10
7
863
8758
6
18
736
7366
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
2.8e-01
9.0e-01
2.2e+00
—
8.9e-01
4.7e-01
4.3e-01
cases:24.34%
controls:19.54%
cases:21.16%
controls:9.87%
cases:11.62%
controls:1.44%
—
—
cases:2.86%
controls:1.19%
cases:14.66%
controls:9.73%
cases:32.88%
controls:24.26%
222
1777
690
7318
193
898
719
8197
106
131
806
8964
—
26
108
884
8959
128
853
745
7912
244
1791
498
5593
Heart failure
I50 [45581779]
6.2e-01
2.0e+00
—
—
—
1.8e+00
1.4e+00
cases:1.10%
controls:0.59%
cases:1.10%
controls:0.15%
—
—
—
—
—
—
cases:1.03%
controls:0.17%
cases:2.56%
controls:0.66%
10
54
902
9041
10
14
902
9081
—
—
—
9
15
864
8750
19
49
723
7335
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
2.8e-01
6.3e-01
1.5e+00
—
1.5e+00
9.0e-01
6.7e-01
cases:8.55%
controls:6.59%
cases:6.36%
controls:3.49%
cases:1.97%
controls:0.45%
—
—
cases:2.09%
controls:0.50%
cases:7.33%
controls:3.13%
cases:16.71%
controls:9.30%
78
599
834
8496
58
317
854
8778
18
41
894
9054
—
19
45
891
9022
64
274
809
8491
124
687
618
6697
Neurology
13 [38004458]
4.5e-01
7.3e-01
1.2e+00
—
1.6e+00
6.2e-01
4.5e-01
cases:14.25%
controls:9.62%
cases:8.00%
controls:4.01%
cases:2.63%
controls:0.79%
—
—
cases:3.41%
controls:0.68%
cases:7.56%
controls:4.20%
cases:14.56%
controls:9.79%
130
875
782
8220
73
365
839
8730
24
72
888
9023
—
31
62
879
9005
66
368
807
8397
108
723
634
6661
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
8.4e-01
9.7e-01
9.7e-01
—
1.7e+00
7.4e-01
8.5e-01
cases:5.37%
controls:2.39%
cases:3.73%
controls:1.45%
cases:1.10%
controls:0.42%
—
—
cases:1.43%
controls:0.28%
cases:2.98%
controls:1.45%
cases:4.31%
controls:1.90%
49
217
863
8878
34
132
878
8963
10
38
902
9057
—
13
25
897
9042
26
127
847
8638
32
140
710
7244
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
1.3e+00
1.7e+00
—
—
—
2.0e+00
1.3e+00
cases:0.55%
controls:0.15%
cases:0.99%
controls:0.18%
—
—
—
—
—
—
cases:1.72%
controls:0.24%
cases:2.56%
controls:0.69%
5
14
907
9081
9
16
903
9079
—
—
—
15
21
858
8744
19
51
723
7333
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
8.4e-01
6.7e-01
2.3e+00
—
2.3e+00
1.5e+00
1.2e+00
cases:1.97%
controls:0.86%
cases:0.88%
controls:0.45%
cases:0.66%
controls:0.07%
—
—
cases:0.55%
controls:0.06%
cases:2.06%
controls:0.49%
cases:4.58%
controls:1.37%
18
78
894
9017
8
41
904
9054
6
6
906
9089
—
5
5
905
9062
18
43
855
8722
34
101
708
7283
Bone marrow Pathology biopsy report
33721-2 [3045142]
—
3.0e+00
—
1.0e+50
1.0e+50
—
1.9e+00
—
—
cases:1.32%
controls:0.07%
—
—
cases:0.66%
controls:0.00%
cases:0.55%
controls:0.00%
—
—
cases:1.21%
controls:0.18%
—
12
6
900
9089
—
6
0
906
9095
5
0
905
9067
—
9
13
733
7371
furosemide; oral, parenteral
C03CA01 [21601518]
9.5e-01
1.0e+00
5.3e-01
—
1.0e+00
1.0e+00
9.1e-01
cases:13.05%
controls:5.49%
cases:11.07%
controls:4.35%
cases:2.08%
controls:1.24%
—
—
cases:3.74%
controls:1.37%
cases:12.26%
controls:4.88%
cases:18.73%
controls:8.49%
119
499
793
8596
101
396
811
8699
19
113
893
8982
—
34
124
876
8943
107
428
766
8337
139
627
603
6757
12 lead EKG panel
34534-8 [3044889]
4.4e-01
7.5e-01
1.5e+00
—
1.1e+00
5.7e-01
5.0e-01
cases:28.29%
controls:20.19%
cases:20.18%
controls:10.64%
cases:5.26%
controls:1.17%
—
—
cases:3.30%
controls:1.17%
cases:16.72%
controls:10.20%
cases:35.98%
controls:25.35%
258
1836
654
7259
184
968
728
8127
48
106
864
8989
—
30
106
880
8961
146
894
727
7871
267
1872
475
5512
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
3.3e-01
2.3e+00
—
—
—
2.5e+00
1.4e+00
cases:0.66%
controls:0.47%
cases:1.32%
controls:0.13%
—
—
—
—
—
—
cases:1.15%
controls:0.09%
cases:1.08%
controls:0.27%
6
43
906
9052
12
12
900
9083
—
—
—
10
8
863
8757
8
20
734
7364
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
2.9e-01
5.1e-01
1.4e+00
—
1.5e+00
8.0e-01
6.6e-01
cases:10.20%
controls:7.80%
cases:6.36%
controls:3.93%
cases:2.19%
controls:0.55%
—
—
cases:2.09%
controls:0.50%
cases:7.67%
controls:3.59%
cases:17.65%
controls:9.99%
93
709
819
8386
58
357
854
8738
20
50
892
9045
—
19
45
891
9022
67
315
806
8450
131
738
611
6646
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
8.8e-01
1.2e+00
1.1e+00
1.0e+50
1.3e+00
1.5e+00
1.2e+00
cases:4.28%
controls:1.81%
cases:3.40%
controls:1.03%
cases:1.10%
controls:0.36%
cases:1.64%
controls:0.00%
cases:0.88%
controls:0.24%
cases:5.38%
controls:1.24%
cases:8.36%
controls:2.65%
39
165
873
8930
31
94
881
9001
10
33
902
9062
15
0
897
9095
8
22
902
9045
47
109
826
8656
62
196
680
7188
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
1.6e+00
9.4e-01
—
—
—
2.0e+00
1.2e+00
cases:3.84%
controls:0.79%
cases:1.32%
controls:0.52%
—
—
—
—
—
—
cases:2.29%
controls:0.33%
cases:4.45%
controls:1.34%
35
72
877
9023
12
47
900
9048
—
—
—
20
29
853
8736
33
99
709
7285
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
1.5e+00
3.1e+00
—
1.0e+50
—
—
1.7e+00
cases:0.66%
controls:0.14%
cases:1.64%
controls:0.08%
—
—
cases:1.75%
controls:0.00%
—
—
—
—
cases:1.62%
controls:0.30%
6
13
906
9082
15
7
897
9088
—
16
0
896
9095
—
—
12
22
730
7362
Overnight pulse oximetry
252568001 [4091874]
1.5e-01
—
—
—
—
3.0e+00
1.8e+00
cases:0.55%
controls:0.47%
—
—
—
—
—
—
—
—
cases:2.18%
controls:0.11%
cases:2.02%
controls:0.35%
5
43
907
9052
—
—
—
—
19
10
854
8755
15
26
727
7358
Leukocytes [#/volume] in Urine
30405-5 [3018095]
2.3e-01
5.8e-01
1.4e+00
—
1.3e+00
8.6e-01
5.4e-01
cases:8.99%
controls:7.28%
cases:7.02%
controls:4.06%
cases:2.19%
controls:0.54%
—
—
cases:2.09%
controls:0.57%
cases:8.36%
controls:3.71%
cases:17.79%
controls:11.20%
82
662
830
8433
64
369
848
8726
20
49
892
9046
—
19
52
891
9015
73
325
800
8440
132
827
610
6557
Essential (primary) hypertension
I10 [45591453]
6.5e-01
7.5e-01
7.9e-01
—
1.0e+00
8.4e-01
6.3e-01
cases:29.28%
controls:17.83%
cases:17.11%
controls:8.87%
cases:3.40%
controls:1.57%
—
—
cases:4.62%
controls:1.70%
cases:19.93%
controls:9.74%
cases:38.27%
controls:24.74%
267
1622
645
7473
156
807
756
8288
31
143
881
8952
—
42
154
868
8913
174
854
699
7911
284
1827
458
5557
Limited function/disability (Y)
Y28 [2002001396]
2.3e+00
—
—
—
—
—
2.3e+00
cases:0.88%
controls:0.09%
—
—
—
—
—
—
—
—
—
—
cases:0.94%
controls:0.09%
8
8
904
9087
—
—
—
—
—
7
7
735
7377
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
-8.3e-02
2.4e+00
—
—
—
—
2.1e+00
cases:0.66%
controls:0.71%
cases:0.99%
controls:0.09%
—
—
—
—
—
—
—
—
cases:2.56%
controls:0.33%
6
65
906
9030
9
8
903
9087
—
—
—
—
19
24
723
7360
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
4.5e-01
6.5e-01
1.5e+00
—
1.0e+00
4.5e-01
4.7e-01
cases:27.41%
controls:19.40%
cases:18.42%
controls:10.56%
cases:4.93%
controls:1.18%
—
—
cases:3.85%
controls:1.43%
cases:16.27%
controls:11.00%
cases:36.52%
controls:26.44%
250
1764
662
7331
168
960
744
8135
45
107
867
8988
—
35
130
875
8937
142
964
731
7801
271
1952
471
5432
valsartan and sacubitril
C09DX04 [1588648]
—
2.3e+00
—
—
—
2.2e+00
1.7e+00
—
—
cases:0.88%
controls:0.09%
—
—
—
—
—
—
cases:0.80%
controls:0.09%
cases:0.94%
controls:0.18%
—
8
8
904
9087
—
—
—
7
8
866
8757
7
13
735
7371
salbutamol; inhalant
R03AC02 [21603256]
6.6e-01
6.8e-01
8.0e-01
—
8.1e-01
8.0e-01
7.2e-01
cases:23.79%
controls:13.86%
cases:13.05%
controls:7.07%
cases:2.52%
controls:1.15%
—
—
cases:2.86%
controls:1.29%
cases:14.89%
controls:7.27%
cases:27.22%
controls:15.41%
217
1261
695
7834
119
643
793
8452
23
105
889
8990
—
26
117
884
8950
130
637
743
8128
202
1138
540
6246
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
3.6e-01
5.1e-01
1.4e+00
—
1.3e+00
4.9e-01
3.8e-01
cases:14.14%
controls:10.34%
cases:9.10%
controls:5.65%
cases:2.96%
controls:0.76%
—
—
cases:2.31%
controls:0.63%
cases:9.51%
controls:6.02%
cases:23.58%
controls:17.36%
129
940
783
8155
83
514
829
8581
27
69
885
9026
—
21
57
889
9010
83
528
790
8237
175
1282
567
6102
Remote monitoring CPAP
WX780 [2001310837]
5.8e-01
9.9e-01
—
—
—
2.4e+00
2.0e+00
cases:0.88%
controls:0.49%
cases:0.77%
controls:0.29%
—
—
—
—
—
—
cases:2.06%
controls:0.18%
cases:4.31%
controls:0.61%
8
45
904
9050
7
26
905
9069
—
—
—
18
16
855
8749
32
45
710
7339
Pharmacy visit
OMOP4822462 [581458]
3.4e-01
7.3e-01
7.4e-01
1.2e+00
8.3e-01
9.6e-01
6.5e-01
cases:94.63%
controls:92.63%
cases:92.00%
controls:84.74%
cases:65.57%
controls:47.53%
cases:7.24%
controls:2.39%
cases:67.58%
controls:47.56%
cases:93.70%
controls:85.05%
cases:96.90%
controls:94.20%
863
8425
49
670
839
7707
73
1388
598
4323
314
4772
66
217
846
8878
615
4312
295
4755
818
7455
55
1310
719
6956
23
428
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
4.4e-01
8.3e-01
2.2e+00
—
—
1.3e+00
8.9e-01
cases:3.40%
controls:2.22%
cases:1.97%
controls:0.87%
cases:1.75%
controls:0.20%
—
—
—
—
cases:3.21%
controls:0.88%
cases:6.33%
controls:2.70%
31
202
881
8893
18
79
894
9016
16
18
896
9077
—
—
28
77
845
8688
47
199
695
7185
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
3.7e-01
5.3e-01
1.4e+00
—
1.3e+00
4.6e-01
3.7e-01
cases:14.47%
controls:10.49%
cases:9.32%
controls:5.73%
cases:3.07%
controls:0.77%
—
—
cases:2.31%
controls:0.65%
cases:9.39%
controls:6.16%
cases:23.58%
controls:17.62%
132
954
780
8141
85
521
827
8574
28
70
884
9025
—
21
59
889
9008
82
540
791
8225
175
1301
567
6083
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
2.8e-01
5.6e-01
1.4e+00
—
1.2e+00
6.1e-01
5.9e-01
cases:12.39%
controls:9.70%
cases:9.32%
controls:5.54%
cases:4.17%
controls:1.02%
—
—
cases:2.42%
controls:0.74%
cases:9.85%
controls:5.60%
cases:20.89%
controls:12.78%
113
882
799
8213
85
504
827
8591
38
93
874
9002
—
22
67
888
9000
86
491
787
8274
155
944
587
6440
Chronic respiratory failure
J96.1 [45557632]
1.1e+00
—
—
—
—
2.2e+00
2.2e+00
cases:0.55%
controls:0.19%
—
—
—
—
—
—
—
—
cases:1.72%
controls:0.19%
cases:2.83%
controls:0.33%
5
17
907
9078
—
—
—
—
15
17
858
8748
21
24
721
7360
Albumin [Mass/volume] in Urine
1754-1 [3012516]
7.8e-01
1.0e+00
1.3e+00
—
3.9e-01
6.2e-01
6.3e-01
cases:15.79%
controls:7.91%
cases:12.94%
controls:5.09%
cases:2.08%
controls:0.60%
—
—
cases:0.88%
controls:0.60%
cases:9.85%
controls:5.54%
cases:22.78%
controls:13.57%
144
719
768
8376
118
463
794
8632
19
55
893
9040
—
8
54
902
9013
86
486
787
8279
169
1002
573
6382
bisoprolol; oral
C07AB07 [21601689]
6.3e-01
6.8e-01
7.1e-01
1.2e+00
8.3e-01
7.2e-01
6.7e-01
cases:27.52%
controls:16.83%
cases:26.21%
controls:15.29%
cases:8.88%
controls:4.55%
cases:0.55%
controls:0.16%
cases:9.78%
controls:4.50%
cases:27.61%
controls:15.64%
cases:33.69%
controls:20.68%
251
1531
661
7564
239
1391
673
7704
81
414
831
8681
5
15
907
9080
89
408
821
8659
241
1371
632
7394
250
1527
492
5857
oxazepam; oral
N05BA04 [21604569]
6.6e-01
9.5e-01
1.1e+00
—
9.6e-01
6.6e-01
8.3e-01
cases:8.22%
controls:4.43%
cases:5.70%
controls:2.29%
cases:1.86%
controls:0.60%
—
—
cases:1.54%
controls:0.60%
cases:4.70%
controls:2.48%
cases:10.65%
controls:4.96%
75
403
837
8692
52
208
860
8887
17
55
895
9040
—
14
54
896
9013
41
217
832
8548
79
366
663
7018
tadalafil; oral
G04BE08 [21602653]
9.2e-01
1.2e+00
1.4e+00
—
7.6e-01
1.3e+00
8.6e-01
cases:3.95%
controls:1.62%
cases:4.17%
controls:1.34%
cases:1.10%
controls:0.29%
—
—
cases:0.66%
controls:0.31%
cases:4.12%
controls:1.20%
cases:6.20%
controls:2.72%
36
147
876
8948
38
122
874
8973
10
26
902
9069
—
6
28
904
9039
36
105
837
8660
46
201
696
7183
Treatment-related counselling outside office
SPAT1249 [2001700350]
5.0e-01
9.9e-01
8.1e-01
—
1.3e+00
7.1e-01
6.6e-01
cases:13.71%
controls:8.82%
cases:7.89%
controls:3.08%
cases:1.21%
controls:0.54%
—
—
cases:1.32%
controls:0.35%
cases:5.73%
controls:2.90%
cases:14.02%
controls:7.76%
125
802
787
8293
72
280
840
8815
11
49
901
9046
—
12
32
898
9035
50
254
823
8511
104
573
638
6811
One hour or less
ZXE00 [2001311394]
5.2e-01
2.8e-01
1.7e+00
—
—
9.1e-01
1.0e+00
cases:10.53%
controls:6.55%
cases:2.30%
controls:1.75%
cases:0.99%
controls:0.18%
—
—
—
—
cases:2.86%
controls:1.18%
cases:8.49%
controls:3.21%
96
596
816
8499
21
159
891
8936
9
16
903
9079
—
—
25
103
848
8662
63
237
679
7147
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
1.1e+00
—
—
—
1.0e+50
2.6e+00
1.5e+00
cases:0.77%
controls:0.25%
—
—
—
—
—
—
cases:0.55%
controls:0.00%
cases:0.80%
controls:0.06%
cases:1.35%
controls:0.30%
7
23
905
9072
—
—
—
5
0
905
9067
7
5
866
8760
10
22
732
7362
Neoplasm of uncertain or unknown behaviour: Kidney
D41.0 [45581311]
—
—
—
—
—
2.2e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.69%
controls:0.08%
cases:1.35%
controls:0.19%
—
—
—
—
—
6
7
867
8758
10
14
732
7370
Gas panel - Arterial blood
24336-0 [3019060]
5.1e-01
1.3e+00
—
1.0e+50
—
1.6e+00
1.2e+00
cases:2.08%
controls:1.26%
cases:1.75%
controls:0.46%
—
—
cases:1.10%
controls:0.00%
—
—
cases:1.60%
controls:0.33%
cases:4.58%
controls:1.45%
19
115
893
8980
16
42
896
9053
—
10
0
902
9095
—
14
29
859
8736
34
107
708
7277
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.2e-01
6.6e-01
1.2e+00
—
1.1e+00
6.6e-01
5.0e-01
cases:7.89%
controls:6.47%
cases:5.37%
controls:2.86%
cases:1.54%
controls:0.48%
—
—
cases:1.43%
controls:0.46%
cases:5.38%
controls:2.86%
cases:11.73%
controls:7.49%
72
588
840
8507
49
260
863
8835
14
44
898
9051
—
13
42
897
9025
47
251
826
8514
87
553
655
6831
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
7.3e-01
9.3e-01
1.2e+00
—
4.1e-01
5.7e-01
6.4e-01
cases:16.01%
controls:8.43%
cases:12.50%
controls:5.31%
cases:2.08%
controls:0.63%
—
—
cases:0.88%
controls:0.58%
cases:9.62%
controls:5.68%
cases:23.72%
controls:14.14%
146
767
766
8328
114
483
798
8612
19
57
893
9038
—
8
53
902
9014
84
498
789
8267
176
1044
566
6340
exenatide; parenteral
A10BJ01 [1123633]
1.2e+00
1.7e+00
—
—
—
2.1e+00
2.0e+00
cases:0.88%
controls:0.26%
cases:0.66%
controls:0.12%
—
—
—
—
—
—
cases:0.80%
controls:0.10%
cases:1.21%
controls:0.16%
8
24
904
9071
6
11
906
9084
—
—
—
7
9
866
8756
9
12
733
7372
Diabetes, insulin-treated
103 [2001600103]
7.2e-01
1.3e+00
—
—
—
1.2e+00
8.7e-01
cases:5.59%
controls:2.80%
cases:2.30%
controls:0.65%
—
—
—
—
—
—
cases:2.06%
controls:0.63%
cases:6.74%
controls:2.93%
51
255
861
8840
21
59
891
9036
—
—
—
18
55
855
8710
50
216
692
7168
Corticotropin [Mass/volume] in Plasma
2141-0 [3035637]
—
—
—
—
—
2.3e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:0.69%
controls:0.07%
cases:1.62%
controls:0.28%
—
—
—
—
—
6
6
867
8759
12
21
730
7363
Handing over of treatment supplies
SPAT1262 [2001700363]
9.8e-01
1.0e+00
8.9e-01
—
9.9e-01
1.1e+00
9.7e-01
cases:11.18%
controls:4.51%
cases:6.36%
controls:2.41%
cases:0.88%
controls:0.36%
—
—
cases:1.32%
controls:0.50%
cases:6.87%
controls:2.42%
cases:10.92%
controls:4.46%
102
410
810
8685
58
219
854
8876
8
33
904
9062
—
12
45
898
9022
60
212
813
8553
81
329
661
7055
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
3.3e-01
5.0e-01
1.4e+00
—
1.2e+00
5.1e-01
3.9e-01
cases:14.25%
controls:10.71%
cases:9.10%
controls:5.74%
cases:3.07%
controls:0.76%
—
—
cases:2.20%
controls:0.66%
cases:9.85%
controls:6.16%
cases:23.85%
controls:17.57%
130
974
782
8121
83
522
829
8573
28
69
884
9026
—
20
60
890
9007
86
540
787
8225
177
1297
565
6087
Medical doctor
Z2221 [2001311556]
4.1e-01
6.1e-01
2.1e+00
—
1.7e+00
1.0e+00
9.3e-01
cases:6.14%
controls:4.15%
cases:2.19%
controls:1.21%
cases:1.21%
controls:0.15%
—
—
cases:0.66%
controls:0.12%
cases:2.63%
controls:0.97%
cases:6.74%
controls:2.76%
56
377
856
8718
20
110
892
8985
11
14
901
9081
—
6
11
904
9056
23
85
850
8680
50
204
692
7180
Fatty (change of) liver, not elsewhere classified
K76.0 [45601189]
1.3e+00
1.6e+00
—
—
—
2.2e+00
1.8e+00
cases:0.99%
controls:0.27%
cases:0.55%
controls:0.11%
—
—
—
—
—
—
cases:0.80%
controls:0.09%
cases:1.48%
controls:0.24%
9
25
903
9070
5
10
907
9085
—
—
—
7
8
866
8757
11
18
731
7366
CPAP therapy
WX723 [2001310826]
1.1e+00
9.2e-01
-1.0e+50
—
—
2.0e+00
2.0e+00
cases:0.99%
controls:0.33%
cases:0.88%
controls:0.35%
cases:0.00%
controls:0.05%
—
—
—
—
cases:2.06%
controls:0.27%
cases:4.58%
controls:0.68%
9
30
903
9065
8
32
904
9063
0
5
912
9090
—
—
18
24
855
8741
34
50
708
7334
spironolactone; oral
C03DA01 [21601534]
8.9e-01
7.7e-01
1.0e+00
—
8.0e-01
1.1e+00
1.3e+00
cases:4.71%
controls:2.00%
cases:3.73%
controls:1.76%
cases:1.21%
controls:0.44%
—
—
cases:1.32%
controls:0.60%
cases:5.27%
controls:1.88%
cases:8.89%
controls:2.70%
43
182
869
8913
34
160
878
8935
11
40
901
9055
—
12
54
898
9013
46
165
827
8600
66
199
676
7185
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
3.8e-01
5.3e-01
—
—
1.9e+00
1.0e+00
9.6e-01
cases:3.07%
controls:2.11%
cases:1.64%
controls:0.98%
—
—
—
—
cases:0.77%
controls:0.11%
cases:2.06%
controls:0.75%
cases:7.01%
controls:2.82%
28
192
884
8903
15
89
897
9006
—
—
7
10
903
9057
18
66
855
8699
52
208
690
7176
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
3.8e-01
5.3e-01
—
—
1.9e+00
1.0e+00
9.6e-01
cases:3.07%
controls:2.11%
cases:1.64%
controls:0.98%
—
—
—
—
cases:0.77%
controls:0.11%
cases:2.06%
controls:0.75%
cases:7.01%
controls:2.82%
28
192
884
8903
15
89
897
9006
—
—
7
10
903
9057
18
66
855
8699
52
208
690
7176
Other chronic obstructive pulmonary disease
J44 [45543268]
7.5e-01
—
—
—
—
2.2e+00
1.7e+00
cases:0.77%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.92%
controls:0.10%
cases:2.16%
controls:0.39%
7
33
905
9062
—
—
—
—
8
9
865
8756
16
29
726
7355
Base excess in Arterial blood by calculation
1925-7 [3003396]
4.5e-01
4.9e-01
—
—
1.9e+00
9.5e-01
1.0e+00
cases:3.18%
controls:2.06%
cases:1.54%
controls:0.95%
—
—
—
—
cases:0.77%
controls:0.11%
cases:1.95%
controls:0.76%
cases:7.41%
controls:2.84%
29
187
883
8908
14
86
898
9009
—
—
7
10
903
9057
17
67
856
8698
55
210
687
7174
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
3.5e-01
4.7e-01
1.6e+00
—
1.4e+00
4.5e-01
3.8e-01
cases:12.28%
controls:8.95%
cases:6.91%
controls:4.43%
cases:2.63%
controls:0.54%
—
—
cases:1.87%
controls:0.45%
cases:6.99%
controls:4.59%
cases:17.79%
controls:12.85%
112
814
800
8281
63
403
849
8692
24
49
888
9046
—
17
41
893
9026
61
402
812
8363
132
949
610
6435
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
6.6e-01
1.1e+00
2.8e+00
—
2.3e+00
8.0e-01
6.7e-01
cases:2.19%
controls:1.14%
cases:1.64%
controls:0.54%
cases:1.21%
controls:0.08%
—
—
cases:0.55%
controls:0.06%
cases:1.26%
controls:0.57%
cases:3.64%
controls:1.90%
20
104
892
8991
15
49
897
9046
11
7
901
9088
—
5
5
905
9062
11
50
862
8715
27
140
715
7244
Endocrinology
46 [38004485]
8.0e-01
9.6e-01
8.7e-01
—
1.0e+00
1.1e+00
1.1e+00
cases:7.46%
controls:3.50%
cases:4.82%
controls:1.90%
cases:0.99%
controls:0.42%
—
—
cases:1.21%
controls:0.43%
cases:5.38%
controls:1.93%
cases:10.65%
controls:3.97%
68
318
844
8777
44
173
868
8922
9
38
903
9057
—
11
39
899
9028
47
169
826
8596
79
293
663
7091
Lipid panel - Serum or Plasma
100898-6 [1761868]
3.9e-01
6.7e-01
1.6e+00
—
5.5e-01
6.7e-01
5.0e-01
cases:12.72%
controls:9.02%
cases:10.20%
controls:5.48%
cases:2.85%
controls:0.56%
—
—
cases:1.10%
controls:0.64%
cases:11.00%
controls:5.97%
cases:22.24%
controls:14.80%
116
820
796
8275
93
498
819
8597
26
51
886
9044
—
10
58
900
9009
96
523
777
8242
165
1093
577
6291
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.3e-01
8.1e-01
1.2e+00
—
6.5e-01
5.0e-01
4.2e-01
cases:35.31%
controls:28.21%
cases:35.75%
controls:19.79%
cases:7.35%
controls:2.44%
—
—
cases:4.51%
controls:2.42%
cases:29.90%
controls:20.57%
cases:51.89%
controls:41.39%
322
2566
590
6529
326
1800
586
7295
67
222
845
8873
—
41
219
869
8848
261
1803
612
6962
385
3056
357
4328
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
2.6e-01
1.0e+00
1.8e+00
—
—
1.0e+00
2.9e-01
cases:3.51%
controls:2.73%
cases:2.63%
controls:0.95%
cases:0.77%
controls:0.13%
—
—
—
—
cases:2.63%
controls:0.95%
cases:3.91%
controls:2.95%
32
248
880
8847
24
86
888
9009
7
12
905
9083
—
—
23
83
850
8682
29
218
713
7166
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
7.2e-01
9.4e-01
1.1e+00
—
2.4e-01
5.5e-01
5.3e-01
cases:16.56%
controls:8.81%
cases:13.27%
controls:5.63%
cases:2.08%
controls:0.70%
—
—
cases:0.88%
controls:0.69%
cases:10.31%
controls:6.24%
cases:23.05%
controls:14.99%
151
801
761
8294
121
512
791
8583
19
64
893
9031
—
8
63
902
9004
90
547
783
8218
171
1107
571
6277
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
3.2e-01
6.8e-01
1.8e+00
—
3.8e-01
7.0e-01
6.7e-01
cases:10.96%
controls:8.19%
cases:7.35%
controls:3.86%
cases:3.07%
controls:0.54%
—
—
cases:0.77%
controls:0.53%
cases:7.33%
controls:3.76%
cases:17.52%
controls:9.76%
100
745
812
8350
67
351
845
8744
28
49
884
9046
—
7
48
903
9019
64
330
809
8435
130
721
612
6663
Left ventricular failure
I50.1 [45543181]
7.2e-01
1.5e+00
—
—
2.3e+00
1.1e+00
8.7e-01
cases:1.10%
controls:0.54%
cases:1.32%
controls:0.30%
—
—
—
—
cases:0.66%
controls:0.07%
cases:1.15%
controls:0.39%
cases:2.29%
controls:0.98%
10
49
902
9046
12
27
900
9068
—
—
6
6
904
9061
10
34
863
8731
17
72
725
7312
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J44.1 [45601132]
1.2e+00
1.5e+00
—
1.0e+50
—
2.2e+00
1.6e+00
cases:0.88%
controls:0.26%
cases:0.66%
controls:0.14%
—
—
cases:0.55%
controls:0.00%
—
—
cases:1.60%
controls:0.18%
cases:2.56%
controls:0.53%
8
24
904
9071
6
13
906
9082
—
5
0
907
9095
—
14
16
859
8749
19
39
723
7345
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3.2e-01
6.5e-01
1.2e+00
—
7.9e-01
3.3e-01
4.3e-01
cases:33.88%
controls:27.05%
cases:26.43%
controls:15.77%
cases:6.03%
controls:1.81%
—
—
cases:4.62%
controls:2.15%
cases:21.42%
controls:16.43%
cases:46.36%
controls:36.02%
309
2460
603
6635
241
1434
671
7661
55
165
857
8930
—
42
195
868
8872
187
1440
686
7325
344
2660
398
4724
High resolution CT examination of lungs
GD1DD [2001303632]
—
1.8e+00
—
—
—
1.7e+00
2.0e+00
—
—
cases:0.77%
controls:0.13%
—
—
—
—
—
—
cases:0.80%
controls:0.15%
cases:2.43%
controls:0.35%
—
7
12
905
9083
—
—
—
7
13
866
8752
18
26
724
7358
Oxygen saturation in Capillary blood
2709-4 [3021901]
—
1.1e+00
—
—
—
1.8e+00
1.9e+00
—
—
cases:0.55%
controls:0.18%
—
—
—
—
—
—
cases:1.26%
controls:0.22%
cases:3.37%
controls:0.50%
—
5
16
907
9079
—
—
—
11
19
862
8746
25
37
717
7347
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
2.8e-01
7.4e-01
1.5e+00
—
9.5e-01
6.1e-01
7.8e-01
cases:7.46%
controls:5.72%
cases:5.81%
controls:2.85%
cases:1.97%
controls:0.44%
—
—
cases:0.88%
controls:0.34%
cases:4.81%
controls:2.68%
cases:13.07%
controls:6.42%
68
520
844
8575
53
259
859
8836
18
40
894
9055
—
8
31
902
9036
42
235
831
8530
97
474
645
6910
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
1.2e-01
9.0e-01
2.7e+00
—
—
3.2e-02
4.7e-01
cases:2.96%
controls:2.63%
cases:2.52%
controls:1.04%
cases:1.32%
controls:0.09%
—
—
—
—
cases:1.26%
controls:1.22%
cases:4.58%
controls:2.93%
27
239
885
8856
23
95
889
9000
12
8
900
9087
—
—
11
107
862
8658
34
216
708
7168
potassium chloride; oral
A12BA01 [21600877]
7.4e-01
9.1e-01
—
—
1.2e+00
1.1e+00
8.9e-01
cases:3.07%
controls:1.48%
cases:2.19%
controls:0.89%
—
—
—
—
cases:0.66%
controls:0.20%
cases:2.75%
controls:0.97%
cases:5.66%
controls:2.40%
28
135
884
8960
20
81
892
9014
—
—
6
18
904
9049
24
85
849
8680
42
177
700
7207
Type 2 diabetes mellitus
E11 [45571656]
8.3e-01
9.8e-01
1.1e+00
—
8.5e-01
9.7e-01
8.0e-01
cases:13.82%
controls:6.55%
cases:6.69%
controls:2.63%
cases:1.21%
controls:0.42%
—
—
cases:0.77%
controls:0.33%
cases:5.84%
controls:2.30%
cases:13.48%
controls:6.51%
126
596
786
8499
61
239
851
8856
11
38
901
9057
—
7
30
903
9037
51
202
822
8563
100
481
642
6903
Inpatient Hospital
21 [8717]
3.8e-01
2.7e-01
7.6e-01
—
1.1e+00
6.9e-01
6.5e-01
cases:36.62%
controls:28.38%
cases:11.62%
controls:9.13%
cases:2.63%
controls:1.24%
—
—
cases:3.52%
controls:1.24%
cases:14.66%
controls:7.96%
cases:30.73%
controls:18.74%
334
2581
578
6514
106
830
806
8265
24
113
888
8982
—
32
112
878
8955
128
698
745
8067
228
1384
514
6000
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
9.9e-02
4.3e-01
1.2e+00
—
9.4e-01
5.0e-01
4.8e-01
cases:19.63%
controls:18.11%
cases:12.72%
controls:8.65%
cases:3.84%
controls:1.19%
—
—
cases:2.97%
controls:1.18%
cases:12.94%
controls:8.24%
cases:29.65%
controls:20.76%
179
1647
733
7448
116
787
796
8308
35
108
877
8987
—
27
107
883
8960
113
722
760
8043
220
1533
522
5851
bupropion; oral
N06AX12 [21604741]
7.9e-01
1.2e+00
9.2e-01
—
1.1e+00
1.0e+00
1.3e+00
cases:2.08%
controls:0.96%
cases:1.86%
controls:0.58%
cases:0.55%
controls:0.22%
—
—
cases:0.55%
controls:0.18%
cases:1.83%
controls:0.65%
cases:4.18%
controls:1.15%
19
87
893
9008
17
53
895
9042
5
20
907
9075
—
5
16
905
9051
16
57
857
8708
31
85
711
7299
Asthma, unspecified
J45.9 [45562456]
5.6e-01
9.5e-01
1.3e+00
—
6.1e-01
1.2e+00
8.2e-01
cases:5.70%
controls:3.35%
cases:3.62%
controls:1.43%
cases:1.10%
controls:0.30%
—
—
cases:0.55%
controls:0.30%
cases:4.70%
controls:1.46%
cases:8.76%
controls:4.05%
52
305
860
8790
33
130
879
8965
10
27
902
9068
—
5
27
905
9040
41
128
832
8637
65
299
677
7085
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
9.3e-01
1.3e+00
—
1.0e+50
—
1.3e+00
1.3e+00
cases:2.08%
controls:0.84%
cases:1.21%
controls:0.32%
—
—
cases:1.32%
controls:0.00%
—
—
cases:1.15%
controls:0.31%
cases:3.37%
controls:0.98%
19
76
893
9019
11
29
901
9066
—
12
0
900
9095
—
10
27
863
8738
25
72
717
7312
Hypertensive heart disease without (congestive) heart failure
I11.9 [45576863]
5.1e-01
1.4e+00
—
1.0e+50
—
2.2e+00
1.4e+00
cases:0.77%
controls:0.46%
cases:0.77%
controls:0.20%
—
—
cases:0.66%
controls:0.00%
—
—
cases:1.83%
controls:0.22%
cases:2.02%
controls:0.53%
7
42
905
9053
7
18
905
9077
—
6
0
906
9095
—
16
19
857
8746
15
39
727
7345
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
6.8e-01
9.4e-01
2.7e+00
—
—
4.1e-01
7.8e-01
cases:1.86%
controls:0.96%
cases:1.21%
controls:0.47%
cases:0.99%
controls:0.07%
—
—
—
—
cases:0.69%
controls:0.46%
cases:3.23%
controls:1.50%
17
87
895
9008
11
43
901
9052
9
6
903
9089
—
—
6
40
867
8725
24
111
718
7273
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
8.8e-01
1.4e+00
—
—
—
1.6e+00
1.9e+00
cases:0.66%
controls:0.27%
cases:0.77%
controls:0.20%
—
—
—
—
—
—
cases:1.26%
controls:0.25%
cases:3.50%
controls:0.56%
6
25
906
9070
7
18
905
9077
—
—
—
11
22
862
8743
26
41
716
7343
semaglutide; oral, parenteral
A10BJ06 [1501778]
1.7e-01
7.1e-01
8.2e-01
—
1.2e+00
1.0e+00
1.2e+00
cases:0.99%
controls:0.84%
cases:2.08%
controls:1.03%
cases:1.32%
controls:0.58%
—
—
cases:1.87%
controls:0.55%
cases:3.21%
controls:1.19%
cases:7.82%
controls:2.41%
9
76
903
9019
19
94
893
9001
12
53
900
9042
—
17
50
893
9017
28
104
845
8661
58
178
684
7206
Nephrology
39 [38004479]
7.0e-01
6.5e-01
3.8e-01
2.6e+00
1.2e+00
6.5e-01
8.7e-01
cases:2.41%
controls:1.21%
cases:1.75%
controls:0.92%
cases:0.55%
controls:0.37%
cases:0.88%
controls:0.07%
cases:0.88%
controls:0.28%
cases:1.95%
controls:1.03%
cases:3.91%
controls:1.68%
22
110
890
8985
16
84
896
9011
5
34
907
9061
8
6
904
9089
8
25
902
9042
17
90
856
8675
29
124
713
7260
Telehealth
OMOP5556618 [722455]
3.8e-01
5.4e-01
9.1e-01
2.3e+00
7.4e-01
5.2e-01
3.7e-01
cases:32.13%
controls:24.54%
cases:14.91%
controls:9.25%
cases:3.73%
controls:1.54%
cases:0.55%
controls:0.05%
cases:3.08%
controls:1.49%
cases:13.17%
controls:8.28%
cases:24.39%
controls:18.19%
293
2232
619
6863
136
841
776
8254
34
140
878
8955
5
5
907
9090
28
135
882
8932
115
726
758
8039
181
1343
561
6041
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
1.0e+00
5.6e-01
—
1.0e+50
1.5e+00
1.5e+00
9.5e-01
cases:2.63%
controls:0.97%
cases:1.10%
controls:0.63%
—
—
cases:0.99%
controls:0.00%
cases:0.66%
controls:0.15%
cases:2.63%
controls:0.62%
cases:3.77%
controls:1.49%
24
88
888
9007
10
57
902
9038
—
9
0
903
9095
6
14
904
9053
23
54
850
8711
28
110
714
7274
moxonidine; oral
C02AC05 [21600401]
1.0e+00
1.2e+00
1.1e+00
—
—
1.1e+00
1.2e+00
cases:2.41%
controls:0.88%
cases:1.75%
controls:0.54%
cases:0.55%
controls:0.18%
—
—
—
—
cases:1.49%
controls:0.52%
cases:2.70%
controls:0.81%
22
80
890
9015
16
49
896
9046
5
16
907
9079
—
—
13
46
860
8719
20
60
722
7324
amlodipine; oral
C08CA01 [21601747]
6.4e-01
6.0e-01
8.6e-01
—
5.5e-01
6.5e-01
6.8e-01
cases:17.98%
controls:10.36%
cases:15.35%
controls:9.05%
cases:5.48%
controls:2.40%
—
—
cases:4.29%
controls:2.51%
cases:16.84%
controls:9.57%
cases:23.72%
controls:13.61%
164
942
748
8153
140
823
772
8272
50
218
862
8877
—
39
228
871
8839
147
839
726
7926
176
1005
566
6379
Monitoring the use of the aid
R5140 [2001310249]
3.0e-01
6.9e-01
—
—
—
1.9e+00
1.5e+00
cases:2.63%
controls:1.97%
cases:1.86%
controls:0.95%
—
—
—
—
—
—
cases:4.24%
controls:0.68%
cases:9.30%
controls:2.14%
24
179
888
8916
17
86
895
9009
—
—
—
37
60
836
8705
69
158
673
7226
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
5.8e-01
6.7e-01
1.7e+00
—
8.2e-01
5.4e-01
4.7e-01
cases:11.29%
controls:6.65%
cases:5.37%
controls:2.81%
cases:1.64%
controls:0.32%
—
—
cases:0.77%
controls:0.34%
cases:5.04%
controls:3.00%
cases:12.67%
controls:8.33%
103
605
809
8490
49
256
863
8839
15
29
897
9066
—
7
31
903
9036
44
263
829
8502
94
615
648
6769
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
5.3e-01
1.3e+00
—
—
—
1.7e+00
1.6e+00
cases:1.21%
controls:0.71%
cases:1.21%
controls:0.34%
—
—
—
—
—
—
cases:1.03%
controls:0.18%
cases:2.96%
controls:0.60%
11
65
901
9030
11
31
901
9064
—
—
—
9
16
864
8749
22
44
720
7340
prazosin; oral
C02CA01 [21600411]
1.6e+00
1.7e+00
—
—
—
1.6e+00
—
cases:1.54%
controls:0.31%
cases:1.10%
controls:0.20%
—
—
—
—
—
—
cases:0.80%
controls:0.17%
—
—
14
28
898
9067
10
18
902
9077
—
—
—
7
15
866
8750
—
formoterol and beclometasone
R03AK08 [43534839]
8.5e-01
1.0e+00
—
—
8.0e-01
1.3e+00
1.0e+00
cases:1.43%
controls:0.62%
cases:1.64%
controls:0.59%
—
—
—
—
cases:0.66%
controls:0.30%
cases:2.52%
controls:0.73%
cases:3.50%
controls:1.27%
13
56
899
9039
15
54
897
9041
—
—
6
27
904
9040
22
64
851
8701
26
94
716
7290
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.9e-01
7.0e-01
2.2e+00
—
—
1.1e+00
6.3e-01
cases:2.30%
controls:1.91%
cases:1.43%
controls:0.71%
cases:0.88%
controls:0.10%
—
—
—
—
cases:2.18%
controls:0.74%
cases:3.64%
controls:1.98%
21
174
891
8921
13
65
899
9030
8
9
904
9086
—
—
19
65
854
8700
27
146
715
7238
Phlebotomy
TPH00 [2001309596]
—
—
—
1.0e+50
1.0e+50
—
3.2e+00
—
—
—
—
—
—
cases:1.21%
controls:0.00%
cases:1.21%
controls:0.00%
—
—
cases:2.02%
controls:0.08%
—
—
—
11
0
901
9095
11
0
899
9067
—
15
6
727
7378
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
7.5e-02
9.9e-01
2.2e+00
—
1.3e+00
5.5e-01
9.5e-02
cases:4.93%
controls:4.60%
cases:5.92%
controls:2.28%
cases:1.97%
controls:0.22%
—
—
cases:0.99%
controls:0.28%
cases:3.78%
controls:2.21%
cases:7.95%
controls:7.29%
45
418
867
8677
54
207
858
8888
18
20
894
9075
—
9
25
901
9042
33
194
840
8571
59
538
683
6846
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2.0e-01
7.6e-01
2.4e+00
—
1.7e+00
5.2e-01
2.5e-01
cases:4.28%
controls:3.52%
cases:3.07%
controls:1.46%
cases:1.21%
controls:0.11%
—
—
cases:0.66%
controls:0.12%
cases:1.83%
controls:1.10%
cases:5.66%
controls:4.47%
39
320
873
8775
28
133
884
8962
11
10
901
9085
—
6
11
904
9056
16
96
857
8669
42
330
700
7054
sitagliptin; oral
A10BH01 [21600784]
8.0e-01
6.9e-01
-8.0e-02
—
7.6e-01
8.0e-01
8.1e-01
cases:5.04%
controls:2.33%
cases:3.62%
controls:1.85%
cases:0.55%
controls:0.59%
—
—
cases:0.99%
controls:0.46%
cases:4.01%
controls:1.85%
cases:5.80%
controls:2.65%
46
212
866
8883
33
168
879
8927
5
54
907
9041
—
9
42
901
9025
35
162
838
8603
43
196
699
7188
Counselling related to known health issue
SPAT1310 [2001700411]
6.0e-01
6.9e-01
1.8e+00
—
1.1e+00
6.1e-01
4.7e-01
cases:9.65%
controls:5.53%
cases:3.18%
controls:1.62%
cases:1.43%
controls:0.24%
—
—
cases:0.55%
controls:0.19%
cases:3.21%
controls:1.77%
cases:7.41%
controls:4.78%
88
503
824
8592
29
147
883
8948
13
22
899
9073
—
5
17
905
9050
28
155
845
8610
55
353
687
7031
Neutrophils [#/volume] in Blood
26499-4 [3017732]
3.5e-01
9.0e-01
2.2e+00
—
9.2e-01
5.6e-01
2.8e-01
cases:1.75%
controls:1.24%
cases:2.30%
controls:0.95%
cases:1.97%
controls:0.23%
—
—
cases:0.55%
controls:0.22%
cases:1.49%
controls:0.86%
cases:3.91%
controls:2.98%
16
113
896
8982
21
86
891
9009
18
21
894
9074
—
5
20
905
9047
13
75
860
8690
29
220
713
7164
Short blood count panel - Blood
55429-5 [40758558]
1.2e-01
7.4e-01
1.7e+00
1.0e+50
8.9e-01
3.8e-01
5.5e-01
cases:7.24%
controls:6.49%
cases:7.24%
controls:3.57%
cases:4.39%
controls:0.82%
cases:0.55%
controls:0.00%
cases:1.65%
controls:0.68%
cases:4.81%
controls:3.35%
cases:11.59%
controls:7.00%
66
590
846
8505
66
325
846
8770
40
75
872
9020
5
0
907
9095
15
62
895
9005
42
294
831
8471
86
517
656
6867
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
7.3e-01
1.1e+00
—
—
1.5e+00
1.1e+00
7.8e-01
cases:2.85%
controls:1.40%
cases:2.52%
controls:0.87%
—
—
—
—
cases:0.66%
controls:0.14%
cases:2.52%
controls:0.84%
cases:5.26%
controls:2.48%
26
127
886
8968
23
79
889
9016
—
—
6
13
904
9054
22
74
851
8691
39
183
703
7201
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.4e-01
6.8e-01
1.5e+00
—
4.6e-01
2.9e-01
2.6e-01
cases:40.57%
controls:34.84%
cases:36.95%
controls:22.81%
cases:10.09%
controls:2.46%
—
—
cases:3.96%
controls:2.54%
cases:29.67%
controls:24.03%
cases:54.18%
controls:47.64%
370
3169
542
5926
337
2075
575
7020
92
224
820
8871
—
36
230
874
8837
259
2106
614
6659
402
3518
340
3866
allopurinol; oral, parenteral
M04AA01 [21604131]
7.5e-01
6.8e-01
8.1e-01
—
8.8e-01
6.3e-01
8.5e-01
cases:6.14%
controls:3.00%
cases:4.39%
controls:2.26%
cases:1.21%
controls:0.54%
—
—
cases:1.21%
controls:0.51%
cases:4.47%
controls:2.42%
cases:8.63%
controls:3.87%
56
273
856
8822
40
206
872
8889
11
49
901
9046
—
11
46
899
9021
39
212
834
8553
64
286
678
7098
vilanterol and fluticasone furoate
R03AK10 [43534841]
7.9e-01
1.0e+00
1.1e+00
—
1.2e+00
1.5e+00
1.4e+00
cases:1.54%
controls:0.70%
cases:1.43%
controls:0.53%
cases:0.77%
controls:0.26%
—
—
cases:0.55%
controls:0.17%
cases:2.41%
controls:0.52%
cases:3.91%
controls:1.03%
14
64
898
9031
13
48
899
9047
7
24
905
9071
—
5
15
905
9052
21
46
852
8719
29
76
713
7308
Hemoglobin [Mass/volume] in Capillary blood
30352-9 [3006184]
9.9e-01
—
1.0e+50
—
—
1.5e+00
1.4e+00
cases:0.77%
controls:0.29%
—
—
cases:0.55%
controls:0.00%
—
—
—
—
cases:1.15%
controls:0.25%
cases:2.29%
controls:0.60%
7
26
905
9069
—
5
0
907
9095
—
—
10
22
863
8743
17
44
725
7340
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
7.1e-01
1.1e+00
—
—
—
1.8e+00
1.1e+00
cases:2.96%
controls:1.48%
cases:0.88%
controls:0.30%
—
—
—
—
—
—
cases:1.60%
controls:0.27%
cases:3.37%
controls:1.14%
27
135
885
8960
8
27
904
9068
—
—
—
14
24
859
8741
25
84
717
7300
insulin glargine; parenteral
A10AE04 [21600739]
7.1e-01
7.1e-01
8.1e-01
-1.0e+50
7.6e-01
8.3e-01
6.0e-01
cases:7.02%
controls:3.56%
cases:6.25%
controls:3.17%
cases:1.97%
controls:0.89%
cases:0.00%
controls:0.08%
cases:1.54%
controls:0.73%
cases:6.99%
controls:3.18%
cases:7.82%
controls:4.46%
64
324
848
8771
57
288
855
8807
18
81
894
9014
0
7
912
9088
14
66
896
9001
61
279
812
8486
58
329
684
7055
insulin (beef); parenteral
A10AD02 [21600730]
7.1e-01
7.1e-01
8.1e-01
-1.0e+50
7.6e-01
8.3e-01
6.0e-01
cases:7.02%
controls:3.56%
cases:6.25%
controls:3.17%
cases:1.97%
controls:0.89%
cases:0.00%
controls:0.08%
cases:1.54%
controls:0.73%
cases:6.99%
controls:3.18%
cases:7.82%
controls:4.46%
64
324
848
8771
57
288
855
8807
18
81
894
9014
0
7
912
9088
14
66
896
9001
61
279
812
8486
58
329
684
7055
hydrocortisone; oral, parenteral
H02AB09 [21602737]
4.1e-01
1.4e+00
2.3e+00
—
—
1.4e+00
7.4e-01
cases:2.30%
controls:1.54%
cases:1.97%
controls:0.48%
cases:0.55%
controls:0.05%
—
—
—
—
cases:2.06%
controls:0.50%
cases:2.96%
controls:1.44%
21
140
891
8955
18
44
894
9051
5
5
907
9090
—
—
18
44
855
8721
22
106
720
7278
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
1.2e+00
1.4e+00
—
—
—
1.5e+00
1.3e+00
cases:0.99%
controls:0.30%
cases:0.88%
controls:0.21%
—
—
—
—
—
—
cases:1.37%
controls:0.30%
cases:3.50%
controls:0.98%
9
27
903
9068
8
19
904
9076
—
—
—
12
26
861
8739
26
72
716
7312
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
285 [2001600217]
6.5e-01
1.5e+00
—
—
—
1.4e+00
1.3e+00
cases:1.75%
controls:0.92%
cases:0.99%
controls:0.22%
—
—
—
—
—
—
cases:0.92%
controls:0.22%
cases:3.64%
controls:0.99%
16
84
896
9011
9
20
903
9075
—
—
—
8
19
865
8746
27
73
715
7311
metformin; oral
A10BA02 [21600747]
4.9e-01
4.5e-01
6.5e-01
—
4.4e-01
4.9e-01
7.3e-01
cases:16.01%
controls:10.42%
cases:14.04%
controls:9.42%
cases:4.71%
controls:2.52%
—
—
cases:4.40%
controls:2.88%
cases:15.01%
controls:9.78%
cases:23.45%
controls:12.81%
146
948
766
8147
128
857
784
8238
43
229
869
8866
—
40
261
870
8806
131
857
742
7908
174
946
568
6438
Outpatient Hospital
22 [8756]
3.0e-01
2.5e-01
6.3e-01
—
1.0e+00
8.0e-01
6.9e-01
cases:28.84%
controls:23.10%
cases:8.55%
controls:6.78%
cases:1.64%
controls:0.88%
—
—
cases:2.09%
controls:0.76%
cases:10.65%
controls:5.09%
cases:24.39%
controls:13.98%
263
2101
649
6994
78
617
834
8478
15
80
897
9015
—
19
69
891
8998
93
446
780
8319
181
1032
561
6352
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.2e-01
6.6e-01
1.5e+00
—
5.9e-01
3.0e-01
3.1e-01
cases:37.72%
controls:32.74%
cases:32.24%
controls:19.74%
cases:8.77%
controls:2.05%
—
—
cases:3.74%
controls:2.11%
cases:26.23%
controls:20.90%
cases:52.02%
controls:44.28%
344
2978
568
6117
294
1795
618
7300
80
186
832
8909
—
34
191
876
8876
229
1832
644
6933
386
3270
356
4114
Fractional oxyhemoglobin in Capillary blood
2715-1 [3022806]
1.3e+00
2.8e+00
—
—
—
2.0e+00
1.6e+00
cases:0.55%
controls:0.15%
cases:0.88%
controls:0.05%
—
—
—
—
—
—
cases:0.57%
controls:0.08%
cases:1.08%
controls:0.23%
5
14
907
9081
8
5
904
9090
—
—
—
5
7
868
8758
8
17
734
7367
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
5.5e-01
1.1e+00
—
—
—
1.5e+00
1.3e+00
cases:1.10%
controls:0.64%
cases:1.32%
controls:0.46%
—
—
—
—
—
—
cases:1.72%
controls:0.39%
cases:2.16%
controls:0.62%
10
58
902
9037
12
42
900
9053
—
—
—
15
34
858
8731
16
46
726
7338
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.8e-01
7.1e-01
1.2e+00
—
5.2e-01
2.9e-01
2.9e-01
cases:38.71%
controls:32.33%
cases:32.57%
controls:19.20%
cases:6.47%
controls:2.10%
—
—
cases:3.41%
controls:2.06%
cases:24.74%
controls:19.81%
cases:48.38%
controls:41.32%
353
2940
559
6155
297
1746
615
7349
59
191
853
8904
—
31
187
879
8880
216
1736
657
7029
359
3051
383
4333
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
2.0e-01
6.4e-01
1.5e+00
—
5.6e-01
2.9e-01
3.1e-01
cases:37.94%
controls:33.26%
cases:32.89%
controls:20.58%
cases:8.77%
controls:2.13%
—
—
cases:3.85%
controls:2.24%
cases:26.80%
controls:21.55%
cases:52.83%
controls:45.11%
346
3025
566
6070
300
1872
612
7223
80
194
832
8901
—
35
203
875
8864
234
1889
639
6876
392
3331
350
4053
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
1.2e+00
—
—
—
—
6.6e-01
1.5e+00
cases:1.32%
controls:0.38%
—
—
—
—
—
—
—
—
cases:0.57%
controls:0.30%
cases:1.62%
controls:0.38%
12
35
900
9060
—
—
—
—
5
26
868
8739
12
28
730
7356
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
1.8e-01
6.0e-01
1.5e+00
—
5.6e-01
3.3e-01
2.7e-01
cases:35.53%
controls:31.48%
cases:27.52%
controls:17.19%
cases:7.57%
controls:1.80%
—
—
cases:3.08%
controls:1.78%
cases:22.79%
controls:17.47%
cases:44.61%
controls:38.18%
324
2863
588
6232
251
1563
661
7532
69
164
843
8931
—
28
161
882
8906
199
1531
674
7234
331
2819
411
4565
Infectious Disease
44 [38004484]
8.0e-01
9.8e-01
1.5e+00
—
—
1.5e-01
9.1e-01
cases:3.73%
controls:1.72%
cases:2.08%
controls:0.79%
cases:0.66%
controls:0.14%
—
—
—
—
cases:0.92%
controls:0.79%
cases:4.45%
controls:1.84%
34
156
878
8939
19
72
893
9023
6
13
906
9082
—
—
8
69
865
8696
33
136
709
7248
Hemoglobin [Entitic mass] in Reticulocytes
42810-2 [3029080]
—
—
—
1.0e+50
—
2.7e+00
1.3e+00
—
—
—
—
—
—
cases:0.77%
controls:0.00%
—
—
cases:1.15%
controls:0.08%
cases:1.08%
controls:0.28%
—
—
—
7
0
905
9095
—
10
7
863
8758
8
21
734
7363
C peptide [Moles/volume] in Serum or Plasma --post meal
55919-5 [40759040]
1.0e+00
—
—
—
—
2.6e+00
—
cases:0.55%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.80%
controls:0.06%
—
—
5
18
907
9077
—
—
—
—
7
5
866
8760
—
metoprolol; oral, parenteral
C07AB02 [21601684]
8.1e-01
5.7e-01
3.1e-01
—
7.9e-01
5.7e-01
7.0e-01
cases:9.98%
controls:4.69%
cases:6.58%
controls:3.85%
cases:1.86%
controls:1.37%
—
—
cases:1.76%
controls:0.81%
cases:6.53%
controls:3.80%
cases:9.16%
controls:4.78%
91
427
821
8668
60
350
852
8745
17
125
895
8970
—
16
73
894
8994
57
333
816
8432
68
353
674
7031
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
7.2e-01
6.8e-01
9.8e-01
—
6.4e-01
6.1e-01
6.0e-01
cases:12.28%
controls:6.36%
cases:5.37%
controls:2.80%
cases:0.99%
controls:0.37%
—
—
cases:1.10%
controls:0.58%
cases:4.47%
controls:2.48%
cases:10.92%
controls:6.31%
112
578
800
8517
49
255
863
8840
9
34
903
9061
—
10
53
900
9014
39
217
834
8548
81
466
661
6918
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
6.1e-01
—
—
—
—
1.5e+00
1.1e+00
cases:1.43%
controls:0.78%
—
—
—
—
—
—
—
—
cases:1.15%
controls:0.26%
cases:1.89%
controls:0.64%
13
71
899
9024
—
—
—
—
10
23
863
8742
14
47
728
7337
Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]
5.7e-01
1.0e+00
—
—
—
1.5e+00
1.1e+00
cases:1.64%
controls:0.93%
cases:0.88%
controls:0.32%
—
—
—
—
—
—
cases:1.26%
controls:0.30%
cases:2.16%
controls:0.76%
15
85
897
9010
8
29
904
9066
—
—
—
11
26
862
8739
16
56
726
7328
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
4.4e-01
9.9e-01
—
—
1.5e+00
8.9e-01
6.4e-01
cases:5.48%
controls:3.58%
cases:4.50%
controls:1.73%
—
—
—
—
cases:0.77%
controls:0.18%
cases:4.24%
controls:1.79%
cases:8.76%
controls:4.82%
50
326
862
8769
41
157
871
8938
—
—
7
16
903
9051
37
157
836
8608
65
356
677
7028
mirtazapine; oral
N06AX11 [21604740]
5.6e-01
6.3e-01
7.6e-01
—
7.3e-01
6.1e-01
7.1e-01
cases:10.31%
controls:6.18%
cases:5.70%
controls:3.12%
cases:1.75%
controls:0.82%
—
—
cases:1.98%
controls:0.96%
cases:6.30%
controls:3.53%
cases:14.15%
controls:7.52%
94
562
818
8533
52
284
860
8811
16
75
896
9020
—
18
87
892
8980
55
309
818
8456
105
555
637
6829
Social phobias
F40.1 [45595907]
1.5e+00
2.5e+00
—
—
—
—
8.2e-01
cases:0.55%
controls:0.12%
cases:0.66%
controls:0.05%
—
—
—
—
—
—
—
—
cases:0.67%
controls:0.30%
5
11
907
9084
6
5
906
9090
—
—
—
—
5
22
737
7362
enalapril; oral, parenteral
C09AA02 [21601786]
5.2e-01
5.9e-01
6.3e-01
—
8.3e-01
5.3e-01
3.7e-01
cases:7.89%
controls:4.86%
cases:6.14%
controls:3.51%
cases:1.86%
controls:1.00%
—
—
cases:2.31%
controls:1.01%
cases:6.07%
controls:3.67%
cases:7.14%
controls:5.07%
72
442
840
8653
56
319
856
8776
17
91
895
9004
—
21
92
889
8975
53
322
820
8443
53
374
689
7010
Volume in Urine collected for unspecified duration
19153-6 [3004775]
7.6e-01
2.5e+00
—
—
—
—
6.1e-01
cases:0.66%
controls:0.31%
cases:0.77%
controls:0.07%
—
—
—
—
—
—
—
—
cases:0.67%
controls:0.37%
6
28
906
9067
7
6
905
9089
—
—
—
—
5
27
737
7357
Collection duration of Urine
13362-9 [3016750]
—
2.5e+00
—
—
—
—
—
—
—
cases:0.77%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
—
7
6
905
9089
—
—
—
—
—
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.6e-01
7.2e-02
—
—
2.5e+00
4.6e-01
3.2e-01
cases:5.26%
controls:4.52%
cases:1.54%
controls:1.43%
—
—
—
—
cases:0.77%
controls:0.07%
cases:1.95%
controls:1.23%
cases:6.20%
controls:4.58%
48
411
864
8684
14
130
898
8965
—
—
7
6
903
9061
17
108
856
8657
46
338
696
7046
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
2.7e-01
6.3e-01
6.8e-01
—
1.3e+00
4.7e-01
5.7e-01
cases:11.40%
controls:8.96%
cases:6.36%
controls:3.50%
cases:1.43%
controls:0.73%
—
—
cases:1.98%
controls:0.57%
cases:6.07%
controls:3.88%
cases:14.69%
controls:8.86%
104
815
808
8280
58
318
854
8777
13
66
899
9029
—
18
52
892
9015
53
340
820
8425
109
654
633
6730
Congestive heart failure
I50.0 [45567179]
7.8e-01
1.1e+00
—
—
—
1.5e+00
9.4e-01
cases:1.43%
controls:0.66%
cases:0.66%
controls:0.23%
—
—
—
—
—
—
cases:1.03%
controls:0.24%
cases:2.96%
controls:1.18%
13
60
899
9035
6
21
906
9074
—
—
—
9
21
864
8744
22
87
720
7297
Mouth breathing
R06.5 [45573006]
6.0e-01
8.2e-01
—
—
—
2.4e+00
4.2e-01
cases:1.54%
controls:0.85%
cases:0.55%
controls:0.24%
—
—
—
—
—
—
cases:1.49%
controls:0.14%
cases:1.21%
controls:0.80%
14
77
898
9018
5
22
907
9073
—
—
—
13
12
860
8753
9
59
733
7325
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
2.5e-01
6.8e-01
1.7e+00
—
4.8e-01
3.2e-01
2.1e-01
cases:8.55%
controls:6.76%
cases:5.59%
controls:2.91%
cases:1.32%
controls:0.24%
—
—
cases:0.55%
controls:0.34%
cases:4.24%
controls:3.10%
cases:11.32%
controls:9.41%
78
615
834
8480
51
265
861
8830
12
22
900
9073
—
5
31
905
9036
37
272
836
8493
84
695
658
6689
felodipine; oral
C08CA02 [21601748]
7.9e-01
6.5e-01
9.8e-01
—
4.4e-01
7.9e-01
8.0e-01
cases:3.84%
controls:1.78%
cases:2.63%
controls:1.39%
cases:0.99%
controls:0.37%
—
—
cases:0.77%
controls:0.50%
cases:3.21%
controls:1.48%
cases:4.04%
controls:1.86%
35
162
877
8933
24
126
888
8969
9
34
903
9061
—
7
45
903
9022
28
130
845
8635
30
137
712
7247
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.3e-01
5.4e-01
1.2e+00
—
5.5e-01
3.2e-01
3.2e-01
cases:23.36%
controls:17.90%
cases:14.14%
controls:8.74%
cases:3.73%
controls:1.18%
—
—
cases:1.65%
controls:0.96%
cases:11.80%
controls:8.82%
cases:29.38%
controls:23.19%
213
1628
699
7467
129
795
783
8300
34
107
878
8988
—
15
87
895
8980
103
773
770
7992
218
1712
524
5672
venlafaxine; oral
N06AX16 [21604745]
7.8e-01
5.4e-01
6.9e-01
—
9.2e-01
8.0e-01
8.0e-01
cases:4.17%
controls:1.96%
cases:1.97%
controls:1.15%
cases:0.66%
controls:0.33%
—
—
cases:0.88%
controls:0.35%
cases:2.86%
controls:1.31%
cases:4.85%
controls:2.25%
38
178
874
8917
18
105
894
8990
6
30
906
9065
—
8
32
902
9035
25
115
848
8650
36
166
706
7218
Person consulting for explanation of investigation findings
Z71.2 [45552100]
2.5e-01
8.0e-01
1.6e+00
—
1.3e+00
6.0e-01
2.3e-01
cases:5.04%
controls:3.99%
cases:3.84%
controls:1.76%
cases:1.10%
controls:0.23%
—
—
cases:0.77%
controls:0.21%
cases:3.32%
controls:1.86%
cases:7.41%
controls:5.99%
46
363
866
8732
35
160
877
8935
10
21
902
9074
—
7
19
903
9048
29
163
844
8602
55
442
687
6942
dabigatran etexilate; oral
B01AE07 [21601026]
1.1e+00
1.2e+00
1.3e+00
—
9.2e-01
1.1e+00
4.7e-01
cases:1.54%
controls:0.51%
cases:1.54%
controls:0.45%
cases:0.77%
controls:0.22%
—
—
cases:0.66%
controls:0.26%
cases:1.37%
controls:0.46%
cases:1.21%
controls:0.76%
14
46
898
9049
14
41
898
9054
7
20
905
9075
—
6
24
904
9043
12
40
861
8725
9
56
733
7328
Elastase.pancreatic [Mass/mass] in Stool
25907-7 [3000570]
1.2e+00
1.2e+00
—
—
—
1.0e+00
1.2e+00
cases:1.43%
controls:0.44%
cases:0.55%
controls:0.16%
—
—
—
—
—
—
cases:0.57%
controls:0.21%
cases:1.89%
controls:0.60%
13
40
899
9055
5
15
907
9080
—
—
—
5
18
868
8747
14
44
728
7340
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
4.4e-01
1.8e-01
9.2e-01
—
1.6e+00
4.5e-01
7.3e-01
cases:4.61%
controls:3.00%
cases:1.75%
controls:1.47%
cases:0.66%
controls:0.26%
—
—
cases:0.99%
controls:0.20%
cases:2.29%
controls:1.47%
cases:7.95%
controls:4.01%
42
273
870
8822
16
134
896
8961
6
24
906
9071
—
9
18
901
9049
20
129
853
8636
59
296
683
7088
Very extensive MRI examination of upper part of abdomen with high intensity magnet
JN1DG [2001305530]
9.7e-01
—
—
—
—
2.3e+00
—
cases:0.55%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.80%
controls:0.08%
—
—
5
19
907
9076
—
—
—
—
7
7
866
8758
—
Insulin-like growth factor-I [Moles/volume] in Serum or Plasma
29775-4 [3014326]
1.1e+00
2.0e+00
—
—
—
2.3e+00
1.5e+00
cases:0.55%
controls:0.19%
cases:0.55%
controls:0.08%
—
—
—
—
—
—
cases:0.80%
controls:0.08%
cases:0.81%
controls:0.19%
5
17
907
9078
5
7
907
9088
—
—
—
7
7
866
8758
6
14
736
7370
Gastroenterology
10 [38004455]
2.8e-01
5.4e-01
5.8e-01
—
1.1e+00
6.7e-01
5.7e-01
cases:7.46%
controls:5.74%
cases:4.50%
controls:2.67%
cases:1.10%
controls:0.62%
—
—
cases:1.43%
controls:0.50%
cases:4.93%
controls:2.58%
cases:11.05%
controls:6.55%
68
522
844
8573
41
243
871
8852
10
56
902
9039
—
13
45
897
9022
43
226
830
8539
82
484
660
6900
Measurement of transcutaneous partial pressure of oxygen
250549007 [4095608]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.11%
—
—
—
—
—
—
8
8
734
7376
Myocardial infarction (acute) UNS no detected stenosis of the coronary artery
I21.90 [2000502438]
2.3e+00
—
—
—
—
—
—
cases:0.77%
controls:0.08%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
905
9088
—
—
—
—
—
—
Schizoaffective disorder, unspecified
F25.9 [45605490]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.94%
controls:0.09%
—
—
—
—
—
—
7
7
735
7377
Adaptation disorder UNS
F43.29 [2000502008]
-1.0e+50
—
—
—
—
—
2.3e+00
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:0.81%
controls:0.08%
0
11
912
9084
—
—
—
—
—
6
6
736
7378
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
346 [2001600307]
9.2e-01
1.0e+00
—
—
—
1.2e+00
1.4e+00
cases:1.86%
controls:0.75%
cases:0.55%
controls:0.20%
—
—
—
—
—
—
cases:0.69%
controls:0.22%
cases:3.50%
controls:0.92%
17
68
895
9027
5
18
907
9077
—
—
—
6
19
867
8746
26
68
716
7316
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
-2.1e-02
1.4e+00
—
—
—
1.3e+00
8.8e-01
cases:1.21%
controls:1.23%
cases:1.43%
controls:0.36%
—
—
—
—
—
—
cases:1.03%
controls:0.29%
cases:2.70%
controls:1.14%
11
112
901
8983
13
33
899
9062
—
—
—
9
25
864
8740
20
84
722
7300
Standard cardiac ultrasound examination
FM1AE [2001303278]
5.7e-01
1.8e-01
—
—
—
9.5e-01
7.3e-01
cases:5.81%
controls:3.38%
cases:1.64%
controls:1.37%
—
—
—
—
—
—
cases:2.98%
controls:1.18%
cases:6.20%
controls:3.10%
53
307
859
8788
15
125
897
8970
—
—
—
26
103
847
8662
46
229
696
7155
Abnormal result investigation NOS
A91 [2002000224]
—
2.2e+00
—
—
—
—
5.1e-01
—
—
cases:1.10%
controls:0.12%
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.65%
—
10
11
902
9084
—
—
—
—
8
48
734
7336
Oxygen content in Arterial blood
19218-7 [3017569]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.21%
controls:0.14%
—
—
—
—
—
—
9
10
733
7374
Ambulatory ECG
XF404 [2001303370]
1.0e+00
8.0e-01
—
—
—
—
1.2e+00
cases:2.85%
controls:1.07%
cases:0.66%
controls:0.30%
—
—
—
—
—
—
—
—
cases:2.43%
controls:0.74%
26
97
886
8998
6
27
906
9068
—
—
—
—
18
55
724
7329
Social worker
Z2446 [2001311559]
-2.7e-01
9.7e-01
—
—
—
2.2e+00
1.1e+00
cases:0.55%
controls:0.71%
cases:0.55%
controls:0.21%
—
—
—
—
—
—
cases:0.92%
controls:0.10%
cases:1.35%
controls:0.45%
5
65
907
9030
5
19
907
9076
—
—
—
8
9
865
8756
10
33
732
7351
Oedema, unspecified
R60.9 [45568143]
8.5e-01
—
—
—
—
2.2e+00
—
cases:0.77%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.80%
controls:0.09%
—
—
7
30
905
9065
—
—
—
—
7
8
866
8757
—
Blood chemistry outside reference range
166318006 [436230]
—
—
1.0e+50
—
—
—
2.2e+00
—
—
—
—
cases:0.99%
controls:0.00%
—
—
—
—
—
—
cases:0.94%
controls:0.11%
—
—
9
0
903
9095
—
—
—
7
8
735
7376
Persons encountering health services in other specified circumstances
Z76.8 [45542457]
2.2e-01
—
—
—
—
2.2e+00
6.1e-01
cases:0.55%
controls:0.44%
—
—
—
—
—
—
—
—
cases:0.69%
controls:0.08%
cases:0.94%
controls:0.51%
5
40
907
9055
—
—
—
—
6
7
867
8758
7
38
735
7346
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.3e-01
3.6e-01
—
—
—
1.2e+00
1.0e+00
cases:2.41%
controls:2.13%
cases:0.99%
controls:0.69%
—
—
—
—
—
—
cases:2.06%
controls:0.66%
cases:5.66%
controls:2.15%
22
194
890
8901
9
63
903
9032
—
—
—
18
58
855
8707
42
159
700
7225
escitalopram; oral
N06AB10 [21604718]
6.5e-01
8.6e-01
8.7e-01
—
1.6e-01
6.7e-01
6.3e-01
cases:6.69%
controls:3.60%
cases:4.28%
controls:1.85%
cases:1.10%
controls:0.46%
—
—
cases:0.66%
controls:0.56%
cases:3.44%
controls:1.78%
cases:5.93%
controls:3.24%
61
327
851
8768
39
168
873
8927
10
42
902
9053
—
6
51
904
9016
30
156
843
8609
44
239
698
7145
Disorders of iron metabolism
E83.1 [45552418]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.81%
controls:0.09%
—
—
—
—
—
—
6
7
736
7377
Crohn disease of large intestine
K50.1 [45601173]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.81%
controls:0.09%
—
—
—
—
—
—
6
7
736
7377
clobetasol
D07AD01 [21602141]
4.9e-01
1.1e+00
1.7e+00
—
1.6e+00
1.1e+00
2.6e-01
cases:3.40%
controls:2.10%
cases:2.41%
controls:0.82%
cases:0.66%
controls:0.12%
—
—
cases:0.66%
controls:0.13%
cases:2.52%
controls:0.89%
cases:3.91%
controls:3.03%
31
191
881
8904
22
75
890
9020
6
11
906
9084
—
6
12
904
9055
22
78
851
8687
29
224
713
7160
rosuvastatin; oral
C10AA07 [21601862]
5.5e-01
5.7e-01
6.5e-02
—
5.5e-01
6.0e-01
4.1e-01
cases:10.31%
controls:6.22%
cases:10.53%
controls:6.23%
cases:1.86%
controls:1.75%
—
—
cases:2.97%
controls:1.73%
cases:11.80%
controls:6.81%
cases:16.44%
controls:11.54%
94
566
818
8529
96
567
816
8528
17
159
895
8936
—
27
157
883
8910
103
597
770
8168
122
852
620
6532
PEEP
WX722 [2001310825]
4.3e-01
—
—
—
—
2.1e+00
9.2e-01
cases:1.10%
controls:0.71%
—
—
—
—
—
—
—
—
cases:1.15%
controls:0.14%
cases:1.35%
controls:0.54%
10
65
902
9030
—
—
—
—
10
12
863
8753
10
40
732
7344
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
5.8e-01
3.5e-01
5.5e-01
—
2.6e-01
7.0e-01
8.1e-01
cases:14.25%
controls:8.48%
cases:4.61%
controls:3.30%
cases:0.99%
controls:0.57%
—
—
cases:0.77%
controls:0.60%
cases:5.73%
controls:2.93%
cases:14.96%
controls:7.27%
130
771
782
8324
42
300
870
8795
9
52
903
9043
—
7
54
903
9013
50
257
823
8508
111
537
631
6847
tizanidine; oral
M03BX02 [21604116]
3.6e-01
6.2e-01
5.6e-01
—
6.4e-01
5.9e-01
5.2e-01
cases:18.09%
controls:13.37%
cases:7.35%
controls:4.10%
cases:1.21%
controls:0.69%
—
—
cases:0.77%
controls:0.41%
cases:6.76%
controls:3.84%
cases:17.12%
controls:10.93%
165
1216
747
7879
67
373
845
8722
11
63
901
9032
—
7
37
903
9030
59
337
814
8428
127
807
615
6577
Pleural effusion, not elsewhere classified
J90 [45605897]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.14%
—
—
—
—
—
—
8
10
734
7374
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
2.5e-01
5.1e-01
1.6e+00
—
4.9e-01
1.7e-01
1.8e-01
cases:12.61%
controls:10.08%
cases:7.89%
controls:4.90%
cases:1.97%
controls:0.42%
—
—
cases:0.99%
controls:0.61%
cases:6.07%
controls:5.19%
cases:16.71%
controls:14.33%
115
917
797
8178
72
446
840
8649
18
38
894
9057
—
9
55
901
9012
53
455
820
8310
124
1058
618
6326
Dental examination
Z01.2 [45581002]
1.2e-01
-3.2e-02
6.6e-01
—
1.7e+00
4.3e-01
4.0e-01
cases:9.54%
controls:8.59%
cases:3.40%
controls:3.51%
cases:0.66%
controls:0.34%
—
—
cases:0.88%
controls:0.17%
cases:5.04%
controls:3.33%
cases:15.23%
controls:10.79%
87
781
825
8314
31
319
881
8776
6
31
906
9064
—
8
15
902
9052
44
292
829
8473
113
797
629
6587

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
505
139
76.43
307.65
1.4
1.3
14.69
45.38
u/l
1.31
450
120
110
106
11.61
101.74
1.1
1.9
—
—
—
0
0
356
1208
4.11
91.31
2.5
2.8
25.38
23.27
%
1.98
331
1134
364
1292
3.95
86.90
2.5
2.7
2.55
2.29
g/l
15.44
338
1202
724
4152
4.13
80.71
7.2
6.3
0.05
0.04
e9/l
12.55
655
3565
372
1398
3.73
80.64
2.7
2.7
15.57
13.29
umol/l
6.04
347
1307
719
4139
4.03
78.85
7.3
6.3
0.65
0.60
e9/l
7.64
651
3553
725
4221
4.03
77.57
7.2
6.4
2.07
1.97
e9/l
0.68
676
3726
727
4274
3.99
75.84
7.6
6.6
0.21
0.20
e9/l
2.18
672
3742
550
2734
3.40
74.84
7.1
6.2
—
—
—
0
0
669
3812
3.55
71.36
7.7
6.6
0.78
0.68
%
4.14
641
3572
668
3809
3.54
71.03
7.6
6.5
2.78
2.90
%
0.70
641
3574
667
3812
3.52
70.39
7.7
6.6
8.71
9.01
%
2.41
639
3581
672
3889
3.49
68.79
7.7
6.5
26.27
27.13
%
1.36
648
3696
73
9
87.85
66.02
1.3
1.4
—
—
—
0
0
655
3828
3.29
63.93
7.4
6.4
58.23
57.67
%
0.66
632
3661
733
4603
3.59
62.92
10.9
9.8
4.63
4.18
e9/l
5.43
659
4003
264
942
3.50
59.62
2.3
2.7
1.78
1.80
%
0.10
235
851
65
72
9.62
53.93
1.1
1.4
—
—
—
0
0
377
1815
2.79
48.91
5.0
4.8
—
—
—
0
0
96
194
5.39
45.80
4.2
3.9
—
—
—
0
0
204
722
3.32
45.58
2.5
2.7
93.00
69.47
e9/l
11.72
156
532
85
162
5.66
43.19
5.8
4.7
3.32
2.59
mmol/l
0.86
60
109
484
2805
2.48
40.91
4.2
3.6
66.68
53.51
mg/l
0.47
347
1871
490
2859
2.47
40.77
5.4
4.3
11.72
9.39
mg/mmol
0.52
333
1845
409
2237
2.45
38.73
3.3
2.8
372.25
355.04
umol/l
2.72
365
1984
566
3584
2.43
38.43
16.9
11.5
0.00
0.00
e9/l
0.56
486
2954
494
2974
2.38
37.23
4.2
3.5
7.98
8.09
mmol/l
0.20
407
2519
636
4347
2.40
34.76
7.8
6.9
13.92
12.00
umol/l
3.52
620
4165
555
3600
2.30
33.99
3.7
3.0
148.58
148.91
ug/l
0.01
521
3350
797
6201
2.77
30.38
10.9
8.5
83.07
79.05
u/l
1.30
768
5893
405
2402
2.20
29.70
5.5
4.4
7.40
7.40
ph
0.26
312
1717
63
130
5.12
29.19
2.8
2.8
4.69
4.30
e9/l
0.69
63
130
55
107
5.39
27.20
1.8
2.2
33.40
33.01
pg
0.22
55
107
168
703
2.69
26.81
4.0
4.6
0.98
0.55
%
0.72
59
208
153
613
2.78
26.55
4.8
3.6
—
—
—
0
0
172
732
2.65
26.52
3.9
4.7
0.93
0.86
%
0.12
60
226
86
245
3.76
26.30
1.8
1.4
6.22
7.79
u/l
0.76
65
197
42
65
6.71
26.18
1.0
1.2
—
—
—
0
0
536
3656
2.07
26.09
8.8
7.3
1.21
1.21
mmol/l
0.74
506
3378
71
178
4.23
25.89
3.2
2.6
19.56
16.53
%
7.48
71
173
166
702
2.65
25.88
4.0
4.8
0.11
0.11
%
0.01
54
196
68
170
4.23
24.88
3.0
2.7
58.72
58.53
%
0.04
68
170
164
707
2.60
24.52
4.2
5.2
0.08
0.12
%
0.26
53
173
150
626
2.66
23.91
4.4
4.1
1.22
1.22
mmol/l
0.28
133
541
573
4079
2.02
23.89
9.2
7.9
1.21
1.21
mmol/l
0.31
469
3529
400
2534
2.00
23.05
4.2
3.2
1384.70
1330.58
ng/l
0.12
334
2152
556
3948
1.98
22.97
22.2
14.6
1.34
1.25
inr
2.89
482
3285
520
3624
1.96
22.52
5.9
5.4
35.60
35.75
g/l
0.25
489
3401
644
4885
1.99
21.11
7.9
5.6
7.23
6.77
mmol/l
5.49
633
4680
219
1141
2.19
21.07
6.6
6.8
1.03
1.03
mmol/l
0.05
207
1058
203
1048
2.19
19.87
5.2
2.4
14.11
13.70
nmol/l
0.26
186
960
81
266
3.24
19.84
2.7
3.1
1.50
1.59
mg/l
0.44
68
243
136
605
2.46
18.78
4.4
3.5
7.41
7.42
ph
0.12
118
512
188
963
2.19
18.67
2.7
2.8
9.12
8.49
umol/l
0.19
171
863
344
2199
1.88
18.28
4.2
3.2
—
0.00
estimate
—
0
11
268
1579
1.97
18.19
3.5
3.0
526.25
547.97
mosm/kgh2o
0.90
235
1382
417
2840
1.83
18.04
4.1
3.6
34.41
35.02
u/l
0.11
402
2677
403
2722
1.83
17.87
4.5
3.4
101.44
76.11
e6/l
0.21
324
2095
304
1884
1.90
17.66
3.8
2.8
4.20
4.27
e6/l
0.05
275
1719
357
2329
1.85
17.66
4.3
3.3
0.54
0.46
e6/l
0.15
282
1714
465
3289
1.81
17.63
5.2
3.8
23.55
42.34
ng/l
4.85
371
2394
64
204
3.29
16.44
2.3
2.3
161.35
131.69
g/l
11.07
57
162
190
1025
2.07
16.32
9.5
9.8
1.88
0.90
mmol/l
1.89
158
846
719
5898
1.90
15.83
5.2
3.9
15.21
14.81
pmol/l
3.79
660
5403
100
423
2.52
15.29
2.9
2.0
32.00
37.67
nmol/l
2.48
100
409
428
3053
1.73
14.97
5.4
4.1
110.23
90.70
e6/l
0.25
337
2193
186
1034
1.99
14.57
9.8
9.8
7.41
7.41
ph
0.12
117
585
235
1431
1.85
13.93
4.4
3.5
0.82
0.82
mmol/l
0.02
224
1357
284
1835
1.78
13.83
2.0
1.7
1.03
1.24
mg/l
0.77
219
1437
29
59
5.04
13.64
1.6
1.9
18.54
19.66
nmol/l
0.25
29
53
306
2055
1.72
12.84
4.8
4.3
83.29
88.97
%
3.23
297
2021
63
231
2.85
12.74
1.9
1.7
233.24
266.41
mu/l
0.62
58
219
339
2345
1.69
12.74
4.7
3.9
0.01
0.01
estimate
0.04
150
796
314
2141
1.70
12.38
3.5
3.2
—
—
—
0
0
145
781
2.01
12.29
2.9
2.0
354.40
373.70
nmol/l
0.64
138
735
545
4283
1.64
12.24
4.6
3.8
0.02
0.02
estimate
0.05
145
806
342
2392
1.67
12.21
5.4
4.4
—
—
—
0
0
371
2653
1.65
12.13
3.4
2.8
50.50
61.38
u/l
3.86
344
2485
542
4265
1.63
12.01
4.6
3.8
8.02
5.95
estimate
0.09
168
888
536
4214
1.62
11.86
4.6
3.8
0.00
0.00
estimate
-0.00
166
873
90
413
2.30
11.46
3.5
3.7
4.66
4.56
pmol/l
0.47
80
374
329
2309
1.65
11.43
4.2
3.2
0.00
0.01
estimate
0.99
137
675
32
83
3.95
11.18
1.8
1.3
26.98
28.35
ng/l
0.09
32
83
146
814
1.94
11.16
8.7
8.4
9.76
9.97
mmol/l
0.16
141
779
125
662
2.02
11.07
2.6
2.9
64.96
66.76
g/l
1.60
112
614
56
212
2.74
10.69
3.4
3.8
9.57
1.84
index
0.88
30
125
61
243
2.61
10.54
2.3
3.9
1.78
2.54
ratio
0.72
30
141
121
646
2.00
10.46
2.3
2.5
9.70
10.92
g/l
2.91
108
599
46
163
2.91
9.93
3.6
3.3
0.78
0.88
nmol/l
0.56
39
136
64
270
2.47
9.84
2.7
4.1
48.38
46.93
mg/l
0.03
49
234
64
271
2.46
9.76
2.7
4.1
48.23
74.60
mg/l
0.59
48
233
805
7170
1.80
9.70
6.6
4.9
1.90
1.92
mu/l
0.18
739
6603
103
534
2.04
9.64
10.8
12.6
24.51
24.35
mmol/l
0.17
103
527
100
516
2.05
9.48
1.6
1.6
1.10
1.46
g/l
1.15
94
483
32
95
3.45
9.24
1.7
1.5
0.20
0.27
nmol/l
0.68
24
71
419
3233
1.53
9.17
4.4
3.7
0.20
0.02
estimate
0.53
147
725
148
884
1.80
9.04
1.7
1.5
—
—
—
0
0
133
770
1.85
8.99
11.1
11.0
—
—
—
0
0
448
3522
1.51
8.90
2.8
2.4
72.51
75.91
nmol/l
1.92
409
3167
288
2063
1.57
8.74
2.8
2.2
5.00
2.93
mg/l
7.41
248
1777
746
6565
1.63
8.71
30.2
19.9
14.42
13.62
%
20.29
741
6492
24
61
4.01
8.64
2.9
2.9
18.82
16.58
%
1.88
24
61
106
584
1.92
8.34
4.3
4.3
97.05
95.56
ng/l
0.06
85
509
349
2635
1.51
8.23
2.4
2.2
250.63
251.08
u/l
0.00
320
2505
857
7871
1.91
8.13
23.8
16.1
21.32
25.19
mg/l
3.35
776
6482
599
5056
1.50
8.09
6.1
4.5
177.43
958.59
e6/l
0.86
14
76
95
510
1.96
8.06
5.1
3.9
23.92
24.24
mmol/l
0.36
95
504
147
907
1.73
7.99
5.3
3.8
7.37
7.38
ph
0.58
85
524
142
868
1.75
7.98
4.8
3.8
1.54
1.87
mmol/l
0.46
128
738
99
544
1.92
7.85
2.3
2.6
—
—
—
0
0
239
1677
1.57
7.81
2.0
1.7
70968168.07
23016874.43
pmol/l
0.45
186
1399
42
162
2.67
7.78
1.6
1.4
—
—
—
0
0
29
92
3.22
7.58
1.3
1.3
0.21
0.18
nmol/l
0.55
21
71
26
77
3.44
7.56
3.4
4.2
18.09
12.11
index
1.06
11
54
833
7622
1.75
7.49
9.9
6.5
42.43
39.53
mmol/mol
10.88
770
7181
318
2401
1.49
7.31
7.6
6.2
—
—
—
0
0
355
2742
1.47
7.26
3.7
3.6
2.37
2.35
mmol/l
1.63
321
2498
649
5644
1.47
6.97
4.3
3.5
62.34
52.80
u/l
1.67
609
5341
868
8081
1.86
6.78
30.0
19.4
139.67
139.73
mmol/l
0.35
862
7944
38
153
2.55
6.50
1.6
1.4
160.50
162.82
au/ml
0.04
12
48
868
8100
1.83
6.46
30.5
19.6
4.00
3.99
mmol/l
0.02
862
7953
441
3616
1.41
6.25
2.1
2.1
89.95
94.99
pmol/l
1.53
245
1956
26
89
2.98
6.03
1.8
1.3
161.72
165.46
pmol/l
0.04
26
89
424
3469
1.40
6.01
2.3
2.0
1.74
1.41
mmol/l
6.82
333
2931
163
1110
1.57
5.94
1.2
1.2
—
—
—
0
0
154
1038
1.58
5.87
4.7
3.4
5.27
5.38
e9/l
0.05
131
907
375
3014
1.40
5.86
2.3
2.2
—
—
—
0
0
99
597
1.73
5.82
12.7
12.3
91.18
94.07
%
3.37
99
592
149
999
1.58
5.81
2.0
1.8
—
—
—
0
0
820
7581
1.60
5.76
5.5
4.4
1.63
1.35
mmol/l
14.18
749
7027
160
1097
1.55
5.65
1.4
1.3
581.43
415.46
titre
0.39
28
238
182
1284
1.52
5.64
1.9
1.9
—
—
—
0
0
829
7695
1.61
5.59
7.0
5.2
6.51
6.02
mmol/l
12.30
759
7094
413
3405
1.38
5.42
3.8
3.4
6.12
6.17
ph
0.48
243
1970
21
68
3.14
5.36
2.5
2.3
573.69
640.20
ml
0.51
13
40
100
629
1.66
5.04
3.5
3.1
299.16
196.43
ng/l
1.50
87
570
24
88
2.77
4.97
1.2
1.3
—
—
nmol/l
—
0
0
28
112
2.55
4.91
2.0
2.2
0.86
0.94
%
—
10
78
51
265
1.98
4.82
1.8
1.4
13.22
24.69
iu/l
3.43
46
218
17
52
3.31
4.76
2.2
2.4
499.50
495.77
min
—
10
35
205
1532
1.43
4.69
1.4
1.4
2.88
2.59
g/l
0.71
145
960
83
510
1.69
4.58
1.3
1.3
161.93
259.44
u/ml
0.93
78
478
38
181
2.15
4.53
1.7
2.0
2.67
4.37
iu/l
1.11
14
72
146
1028
1.50
4.53
1.5
1.5
—
—
—
0
0
18
59
3.09
4.53
1.1
1.1
—
—
—
0
0
56
308
1.87
4.49
2.6
2.1
22.47
20.66
s
0.71
49
277
44
223
2.02
4.47
2.4
2.4
63.99
143.22
ug/min
0.97
23
134
97
625
1.61
4.46
2.6
2.5
5.94
6.07
ph
0.71
65
423
132
918
1.51
4.35
1.8
1.7
—
—
—
0
0
32
145
2.25
4.32
1.4
1.3
63.36
60.07
mmol/l
0.19
25
123
854
8072
1.57
4.30
7.5
5.9
2.55
2.70
mmol/l
5.51
790
7541
26
108
2.45
4.25
3.2
2.5
2.96
1.30
g/24h
1.66
15
71
146
1042
1.47
4.24
1.3
1.3
—
—
—
0
0
55
307
1.84
4.23
1.2
1.2
—
—
—
0
0
148
1063
1.46
4.16
1.7
1.6
—
—
—
0
0
840
7925
1.52
4.11
6.5
5.1
1.20
1.40
mmol/l
47.81
776
7390
69
417
1.71
4.07
4.3
3.6
—
—
—
0
0
843
7964
1.52
4.04
6.6
5.2
4.29
4.58
mmol/l
14.90
784
7470
32
150
2.17
4.00
1.2
1.1
252.20
79.06
iu/ml
—
10
28
167
1238
1.42
3.96
2.1
2.2
—
—
—
0
0
177
1327
1.41
3.94
2.8
2.2
31.88
29.63
s
2.89
171
1294
91
598
1.58
3.88
13.5
12.1
1.68
1.33
%
1.97
91
593
34
166
2.09
3.85
1.3
1.2
312.38
285.08
u/ml
0.20
24
95
102
692
1.53
3.78
1.4
1.4
—
—
—
0
0
46
252
1.87
3.78
1.7
1.4
286.33
274.97
ug/g
0.12
27
160
61
368
1.70
3.64
1.8
1.9
0.58
2.25
ug/l
1.36
54
326
36
184
1.99
3.62
1.3
1.3
38.31
1181.48
e6/l
0.90
29
141
62
379
1.68
3.54
1.7
1.9
1.34
1.54
g/l
1.09
57
333
35
180
1.98
3.47
1.3
1.2
10.58
14.89
e6/l
0.20
26
131
32
160
2.03
3.43
4.2
4.4
9.55
9.87
pmol/l
0.09
32
160
43
240
1.83
3.36
1.4
1.3
—
—
—
0
0
438
3817
1.27
3.35
5.3
5.1
1.81
2.26
ug/l
1.75
398
3464
874
8373
1.55
3.34
17.5
12.2
34.19
28.29
u/l
5.15
854
8161
34
177
1.96
3.27
1.2
1.7
—
—
—
0
0
77
513
1.55
3.13
12.9
13.3
17.72
16.06
%
4.36
77
494
50
299
1.71
3.12
5.4
4.2
1.36
1.40
mmol/l
0.12
50
291
27
132
2.08
3.09
1.8
2.3
—
—
—
0
0
174
1353
1.35
3.08
4.2
3.1
2.87
1.63
e6/l
0.56
93
678
187
1472
1.34
3.05
4.2
3.0
0.99
0.92
e6/l
0.08
108
798
109
794
1.42
2.86
2.6
2.5
38.50
40.43
u/l
0.08
96
674
19
83
2.32
2.85
1.1
1.2
—
—
—
0
0
24
116
2.10
2.84
1.4
1.2
—
—
—
0
0
18
77
2.36
2.83
1.4
1.3
—
—
—
0
0
201
1617
1.31
2.81
5.2
4.0
1535.73
530.98
ng/l
0.36
157
1289
170
1336
1.33
2.80
1.9
1.7
1135.71
1179.05
nmol/l
0.25
129
1017
424
3743
1.24
2.72
3.2
2.8
—
—
estimate
—
0
0
26
133
1.98
2.67
1.2
1.1
0.57
1.72
u/ml
0.85
17
77
195
1573
1.30
2.66
3.0
3.1
2.48
2.44
mmol/l
3.69
168
1416
128
972
1.37
2.64
1.4
1.4
—
—
—
0
0
379
3315
1.24
2.62
4.3
3.2
—
—
—
0
0
30
163
1.87
2.60
3.6
3.8
11.77
27.74
mg/l
4.66
22
110
5
7
7.17
2.55
1.0
1.4
—
—
—
0
0
15
62
2.44
2.55
1.2
1.2
—
—
—
0
0
26
136
1.94
2.52
2.1
1.7
0.92
0.81
g/l
0.18
17
110
51
326
1.60
2.51
4.2
4.0
25.09
24.87
mmol/l
0.24
45
303
17
76
2.26
2.45
1.4
1.3
5.46
6.64
g/l
—
8
56
17
76
2.26
2.45
1.4
1.3
0.35
0.37
g/l
—
8
55
17
76
2.26
2.45
1.4
1.3
2.35
2.90
g/l
—
8
55
209
1720
1.28
2.44
1.3
1.3
0.84
1.82
u/ml
1.84
75
491
113
854
1.37
2.41
1.7
1.5
—
—
—
0
0
53
346
1.56
2.40
1.2
1.3
—
—
—
0
0
22
111
2.01
2.37
1.8
1.5
—
—
—
0
0
22
111
2.01
2.37
1.8
1.5
—
—
—
0
0
22
111
2.01
2.37
1.8
1.5
—
—
—
0
0
22
111
2.01
2.37
1.8
1.5
—
—
—
0
0
34
199
1.73
2.34
1.1
1.8
1.04
0.89
nmol/l
0.54
29
170
19
91
2.11
2.34
2.7
3.2
4.69
4.94
nmol/l
0.04
19
91
14
59
2.39
2.30
1.2
1.4
—
—
—
0
0
18
85
2.14
2.30
1.2
1.1
—
—
—
0
0
12
47
2.57
2.27
1.6
1.2
0.51
0.51
ratio
—
5
28
16
73
2.21
2.22
1.4
1.5
553.09
295.73
mu/l
0.42
11
56
10
35
2.88
2.21
5.5
4.3
—
—
—
0
0
66
461
1.46
2.21
1.3
1.2
147.25
133.68
u/ml
0.07
20
178
302
2619
1.22
2.19
2.7
2.5
—
—
—
0
0
83
612
1.39
2.08
1.6
1.5
—
—
—
0
0
28
161
1.76
2.07
1.3
1.2
—
—
—
0
0
10
37
2.72
2.07
6.7
7.3
3.28
25.48
ug/l
—
5
27
5
10
5.02
2.07
1.2
1.1
—
—
—
0
0
70
509
1.41
1.92
2.0
1.8
—
—
—
0
0
22
121
1.84
1.89
1.8
1.2
4.00
5.61
u/ml
0.29
12
57
14
65
2.17
1.88
1.5
1.4
—
—
—
0
0
45
301
1.52
1.88
3.1
4.0
1196.03
244.64
mg/l
0.61
31
140
11
46
2.41
1.85
4.1
2.6
—
—
—
0
0
22
122
1.82
1.85
2.0
2.8
—
—
—
0
0
265
2303
1.21
1.85
1.5
1.4
—
—
—
0
0
13
59
2.22
1.84
1.1
1.2
43.64
45.10
mg/l
—
7
49
56
394
1.45
1.84
1.3
1.2
—
—
—
0
0
8
29
2.77
1.79
1.0
1.2
—
—
—
0
0
33
208
1.61
1.79
1.2
1.3
116.43
217.59
miu/ml
1.18
12
85
65
473
1.40
1.79
1.1
1.1
—
—
—
0
0
61
443
1.40
1.71
1.5
1.7
0.19
0.33
mg/l
3.18
32
225
17
89
1.93
1.70
3.2
2.3
—
—
—
0
0
17
89
1.93
1.70
3.1
2.3
—
—
—
0
0
8
31
2.59
1.66
1.4
1.7
—
—
—
0
0
7
25
2.81
1.65
1.3
3.3
3.00
5.60
ug/l
—
7
25
14
69
2.04
1.65
1.1
1.1
—
—
—
0
0
5
14
3.58
1.61
1.8
2.1
—
—
—
0
0
5
14
3.58
1.61
1.0
1.1
—
—
—
0
0
7
26
2.70
1.58
1.6
1.3
33.71
27.65
s
—
7
26
12
57
2.12
1.55
1.0
1.2
0.02
0.38
u/ml
—
6
32
39
267
1.48
1.51
1.4
1.6
12.62
11.46
u/ml
—
5
62
16
86
1.88
1.51
1.3
1.2
—
—
—
0
0
882
8614
1.33
1.50
39.3
24.4
243.94
244.26
e9/l
0.04
877
8463
27
170
1.61
1.50
1.8
1.5
—
—
—
0
0
14
72
1.96
1.49
2.1
1.4
26.13
25.35
%
—
7
48
882
8618
1.33
1.46
39.4
24.4
7.74
6.76
e9/l
24.94
875
8441
882
8618
1.33
1.46
39.3
24.3
5.27
4.56
e12/l
137.80
874
8442
53
388
1.39
1.45
4.0
3.5
1.02
1.02
ratio
0.00
39
365
14
73
1.93
1.44
3.3
2.8
1139.93
1285.74
mg
0.14
14
73
6
22
2.74
1.43
1.7
1.4
33.83
24.36
%
—
6
22
6
22
2.74
1.43
1.2
1.2
46.00
66.41
nmol/24h
—
6
22
24
149
1.63
1.42
1.0
1.1
—
—
—
0
0
7
29
2.42
1.39
1.0
1.1
—
—
—
0
0
13
67
1.95
1.38
1.3
1.5
75.92
82.10
umol/l
0.45
13
67
264
2349
1.17
1.38
1.8
1.7
17.91
19.75
nmol/l
1.48
226
1978
259
2303
1.17
1.37
3.3
3.0
0.72
0.73
ug/l
0.17
165
1388
105
856
1.25
1.36
3.9
4.7
4.42
23.98
ug/l
1.35
95
721
93
748
1.27
1.35
2.7
2.3
10.39
7.93
ug/l
0.28
78
672
10
47
2.14
1.34
1.0
1.0
—
—
—
0
0
12
61
1.98
1.33
1.6
2.0
41.52
41.14
%
0.03
12
61
25
160
1.58
1.32
1.1
1.1
—
—
—
0
0
15
83
1.82
1.32
1.1
1.4
10.60
26.24
u/l
2.61
15
67
9
44
2.06
1.27
1.1
1.1
164.11
141.03
nmol/l
—
9
44
44
321
1.39
1.25
1.6
1.9
7.01
6.66
iu/ml
—
7
80
95
774
1.25
1.25
2.3
2.2
0.00
0.02
estimate
0.50
25
160
117
978
1.22
1.22
2.4
2.6
99.76
125.11
ug/g
0.88
99
800
21
321
0.65
1.18
1.0
1.1
1.34
1.49
g/l
1.39
21
321
7
30
2.34
1.12
1.0
1.0
—
—
—
0
0
7
31
2.27
1.10
3.7
3.1
0.60
0.60
mmol/l
—
7
31
14
81
1.74
1.09
1.9
2.4
—
—
—
0
0
15
89
1.70
1.08
1.3
1.7
—
—
—
0
0
23
336
0.68
1.06
1.3
1.2
0.87
0.91
g/l
0.37
23
336
15
90
1.68
1.04
2.1
1.6
61.87
62.47
%
—
8
60
5
22
2.28
1.03
20.6
7.5
7.20
5.25
kpa
—
5
22
18
114
1.59
1.03
1.3
1.2
—
—
—
0
0
47
361
1.32
1.01
3.1
2.7
—
—
—
0
0
19
283
0.66
0.97
1.1
1.1
—
—
—
0
0
7
36
1.95
0.97
1.6
1.6
—
3232.00
—
0
5
37
276
1.35
0.97
1.7
2.6
—
—
—
0
0
9
52
1.74
0.92
2.7
1.8
89.33
106.83
ng/l
—
9
52
15
94
1.61
0.91
1.3
1.4
—
—
—
0
0
17
111
1.54
0.88
1.0
1.1
0.66
1.29
u/ml
—
10
63
153
1354
1.15
0.88
1.3
1.3
6.46
10.40
u/ml
0.46
66
540
15
95
1.59
0.87
2.2
1.9
11.85
10.61
%
0.37
15
95
45
352
1.29
0.87
2.8
1.8
—
—
—
0
0
6
31
1.94
0.84
1.0
1.0
—
—
—
0
0
55
676
0.80
0.84
1.7
1.8
3.24
3.50
mmol/l
0.82
39
499
12
73
1.65
0.82
1.1
1.2
—
—
—
0
0
38
294
1.30
0.81
1.7
2.5
—
—
—
0
0
63
759
0.82
0.81
1.7
1.4
—
—
—
0
0
0
24
0.00
0.79
0.0
2.0
—
10.03
—
0
18
0
25
0.00
0.79
0.0
2.2
—
4838.38
—
0
13
38
299
1.28
0.73
1.7
2.4
—
—
—
0
0
38
299
1.28
0.73
1.7
2.5
—
—
—
0
0
7
39
1.80
0.72
1.4
1.7
—
—
—
0
0
10
60
1.67
0.72
1.8
1.1
78.00
102.52
pmol/l
—
10
60
12
76
1.59
0.72
1.4
1.1
—
—
—
0
0
7
41
1.71
0.70
1.0
1.3
138.71
184.82
mmol/24h
—
7
41
7
42
1.67
0.68
1.1
1.1
179.34
252.46
iu/ml
—
7
42
26
196
1.34
0.68
1.2
1.2
—
—
—
0
0
17
119
1.44
0.67
1.0
1.1
3.72
6.25
u/ml
—
6
65
37
296
1.26
0.64
1.7
2.3
—
—
—
0
0
66
563
1.19
0.63
2.4
2.5
25.18
19.39
au/ml
—
5
59
28
217
1.30
0.62
1.3
1.2
—
—
—
0
0
162
1477
1.12
0.62
1.3
1.3
17.34
30.22
iu/ml
3.68
49
440
5
30
1.67
0.61
1.2
1.4
0.00
1.38
%
—
5
25
0
20
0.00
0.60
0.0
1.5
—
28.22
—
0
15
0
21
0.00
0.60
0.0
5.5
—
8.62
—
0
21
0
21
0.00
0.60
0.0
2.8
—
43.67
—
0
21
206
1907
1.10
0.59
4.2
3.9
1.02
1.02
kg/l
0.12
149
1285
0
22
0.00
0.59
0.0
1.2
—
137.81
—
0
16
16
114
1.41
0.59
1.0
1.1
0.13
1.08
u/ml
—
5
51
42
346
1.22
0.58
2.4
3.9
122.80
4308.26
u/ml
0.82
35
295
13
89
1.47
0.58
1.2
1.1
—
—
—
0
0
34
419
0.80
0.58
2.1
2.4
0.00
1.95
estimate
0.51
13
130
36
292
1.24
0.57
2.9
2.7
22.23
81.32
u/ml
0.83
36
279
9
61
1.48
0.53
1.3
1.1
—
—
—
0
0
6
39
1.54
0.53
1.0
1.0
1796.83
1516.18
miu/ml
—
6
39
17
127
1.34
0.50
2.3
3.2
—
—
—
0
0
14
101
1.39
0.49
1.0
1.1
2.87
2.18
u/ml
—
8
57
14
102
1.38
0.47
3.9
2.6
—
—
—
0
0
27
221
1.23
0.42
1.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.5
—
—
—
0
0
5
34
1.47
0.40
2.2
1.3
0.60
0.09
estimate
—
5
34
5
35
1.43
0.39
1.0
1.3
116.60
111.65
nmol/l
—
5
26
9
66
1.37
0.38
1.3
1.1
—
—
—
0
0
9
69
1.31
0.37
1.0
1.0
—
—
—
0
0
27
228
1.19
0.33
1.2
1.2
—
—
—
0
0
12
92
1.31
0.32
1.0
1.1
0.51
2.31
u/ml
—
6
45
12
93
1.29
0.30
1.3
1.3
30960.00
17611.22
e6/l
—
5
49
13
103
1.27
0.28
1.4
1.3
3133.29
1760.53
e6/l
—
7
64
17
140
1.22
0.27
1.0
1.1
13.92
20.83
au/ml
—
5
40
11
87
1.27
0.24
1.4
1.4
—
—
—
0
0
5
42
1.19
0.21
1.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
17.31
—
0
12
0
13
0.00
0.21
0.0
1.0
—
18.67
—
0
6
27
240
1.13
0.20
1.4
1.6
14952.06
16777.18
e6/l
0.14
17
168
0
14
0.00
0.20
0.0
1.9
—
0.25
—
0
5
53
567
0.93
0.17
1.1
1.2
—
—
—
0
0
17
148
1.15
0.17
1.2
1.1
—
—
—
0
0
17
148
1.15
0.17
1.2
1.1
—
—
—
0
0
5
70
0.71
0.16
1.2
1.2
—
—
—
0
0
13
111
1.17
0.16
1.2
1.2
—
—
—
0
0
48
513
0.93
0.15
1.2
1.3
—
—
—
0
0
7
86
0.81
0.14
2.4
2.1
—
—
—
0
0
12
103
1.17
0.13
1.2
1.1
—
—
—
0
0
20
180
1.11
0.13
11.3
9.5
11.75
11.50
mmol/l
0.10
20
163
20
180
1.11
0.13
11.3
9.5
104.70
105.40
mmol/l
0.31
20
163
10
87
1.15
0.09
1.6
1.2
—
—
—
0
0
10
87
1.15
0.09
1.0
1.0
0.00
0.29
u/ml
—
5
39
5
48
1.04
0.09
1.2
1.5
—
—
—
0
0
28
264
1.06
0.07
1.3
1.6
—
—
—
0
0
9
87
1.03
0.07
1.0
1.2
—
—
—
0
0
12
109
1.10
0.06
1.2
1.1
17.34
2.70
eliau/ml
—
5
42
39
375
1.04
0.06
2.3
2.4
—
—
—
0
0
20
189
1.06
0.04
5.8
4.6
—
—
—
0
0
77
754
1.02
0.04
4.8
4.2
7.37
7.35
ph
0.85
59
551
26
251
1.04
0.02
19.6
10.5
—
—
—
0
0
35
341
1.03
0.02
1.5
1.6
—
—
—
0
0
15
149
1.01
0.00
1.4
1.4
—
—
—
0
0
7
74
0.95
0.00
1.1
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
245.82
—
0
6
9
95
0.95
-0.00
1.1
1.4
7.29
6.24
mmol/l
—
9
90
8
88
0.91
-0.00
1.8
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.06
—
0
6
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
402.00
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
0.16
—
0
5
0
5
0.00
-0.00
0.0
2.6
—
194.80
—
0
5
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint D3_SCNDPOLYCYTHAEMIA and mortality.

Females

Parameter HR [95% CI] p-value
D3_SCNDPOLYCYTHAEMIA 2.337 [1.94, 2.81] < 0.001
Birth year 0.998 [0.99, 1.01] 0.556

During the follow-up period (1.1.1998 — 31.12.2019), 330 out of 1298 females with D3_SCNDPOLYCYTHAEMIA died.

Males

Parameter HR [95% CI] p-value
D3_SCNDPOLYCYTHAEMIA 1.929 [1.65, 2.25] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 574 out of 2522 males with D3_SCNDPOLYCYTHAEMIA died.

Mortality risk

Mortality risk for people of age

years, who have D3_SCNDPOLYCYTHAEMIA.

N-year risk Females Males
1 0.314% 0.369%
5 1.509% 2.132%
10 3.477% 5.162%
15 6.641% 10.023%
20 12.368% 16.089%

Relationships between endpoints

↥

Index endpoint: D3_SCNDPOLYCYTHAEMIA – Secondary polycythaemia

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data